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ABSTRACT 
 Head and neck squamous cell carcinomas (HNSCC) are a group of anatomically diverse 
cancers characterized by their resistance to traditional chemotherapy and radiotherapy 
modalities. Given that as diagnostic and therapeutic strategies in cancer treatment have seen 
great improvements over the last several decades, it would be only logical that the prognosis of 
HNSCC should improve. However, this has not been the case as the prognosis for HNSCC has 
remained unchanged over the last several decades, highlighting a need for new treatment 
strategies. One potential strategy that has demonstrated potential in a variety of other solid 
tumors is NQO1-targeted therapy. In this strategy the overexpression of NQO1 can be taken 
advantage of by the DNQ derivative IB-DNQ which is a futile substrate for NQO1 that generates 
high levels of cytotoxic ROS selectively inside the cancer cell. Given the high prevalence of 
NQO1 in HNSCC tumors this appears to be a promising strategy for treating this disease. 
 Described in Chapter 2 is the evaluation of IB-DNQ in HNSCC cell lines as well as in 
feline oral squamous cell carcinoma cell lines FOSCC). The effectiveness of IB-DNQ was found 
to be directly correlated with the expression of NQO1 in these cell lines. The pharmacokinetic 
profile and tolerability of IB-DNQ was determined in healthy research cats and parameters from 
these analyses were used to conduct in vitro experiments to mimic these conditions. These 
experiments showed that tumors expressing NQO1 should respond to treatment with IB-DNQ. 
Preliminary treatments of cats with FOSCC with IB-DNQ as a single agent, as well as in 
combination with ionizing radiation have yielded positive/promising responses in several cats. 
 Described in Chapter 3 is the investigation into enhancing the current therapeutic window 
of NQO1-targeted therapy. A prodrug approach to IB-DNQ was attempted to increase solubility 
and/or reduce off-target toxicity. A secondary approach involving the synthesis of novel 
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derivatives of IB-DNQ containing modifications at a site not previously explored in the SAR of 
the molecule was also conducted. While the few derivatives synthesized to date all have 
experienced loss in potency, this site is primed for further investigation and derivatization. 
Finally, an approach revisiting previously synthesized derivatives of DNQ was implemented in 
attempts to find a derivative with a greater maximum tolerated dose (MTD) or more favorable 
pharmacokinetics.  
Future studies involving NQO1-independent ROS generation, methemoglobin formations 
and tumor penetrations are currently being investigated to differentiate DNQ derivatives and 
identify a lead compound. Ongoing clinical evaluation of NQO1-targeted therapy in feline 
OSCC aims to establish IB-DNQ as an effective treatment modality as well as strengthen its case 
for translation into humans.   
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Chapter 1. Assessing the potential of NQO1 therapy for head and neck cancer 
 
1.1. Addressing the lack of prognostic improvement in head and neck cancer 
Head and neck cancers describe a collection of cancers arising in diverse anatomical 
locations in the head and neck. These include cancers of the pharynx (hypo, oro and naso), 
larynx, oral cavity, paranasal sinuses as well as the nasal cavity and salivary glands,
1,2
 the 
majority which are of squamous cell differentiation.
1,3
 Worldwide head and neck squamous cell 
carcinomas (HNSCC) comprise the sixth most diagnosed malignancy and account for nearly 
300,000 deaths annually.
4-8
 When diagnosed early, these cancers are very treatable, evidenced by 
the 80% 5-year survival rate in this group of individuals.
5
 Unfortunately early diagnosis 
describes less than a third of all such malignancies and much more frequently the tumor is 
diagnosed in the later stages of the disease, where it has become locally advanced, and the 5-year 
survival rate plummets below 50%.
5
 Despite improvements in both diagnostic and treatment 
modalities over the last several decades,
9-12
 there has not been a significant change in prognosis 
for those with head and neck cancers.
2,13 
 
1.1.1. Treatment of HNSCC 
 The current standard of care for HNSCC is surgical resection of the tumor; however, 
surgery is only effective when used in treating early stage tumors.
2,14,15
 Radiotherapy, showing 
comparable outcomes to that of surgery,
16,17
 has also seen clinical use for early stage tumors. In 
advanced or late stage malignancies it becomes necessary to use a radiotherapy-surgery 
combined modality treatment for improvement in outcome.
15,18-21
 Unfortunately, approximately 
40% of these advanced HNSCCs are unresectable
22,23
 due to either (1) the inability to medically 
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operate on the tumor region, (2) the potential adverse effects of resection on the patient’s 
functional faculties including speech and swallowing or (3) the potential adverse effects of 
resection on the patient’s cosmetic appearance. In these cases, concomitant chemoradiation using 
ionizing radiation (IR) and a platinum-based antineoplastic agent (most commonly cisplatin) is 
used.
24-26
 However, given the lack of prognostic change seen in HNSCC for several decades with 
these treatment modalities, there is an urgent need for new treatment modalities for HNSCC, 
especially for late stage disease.  
 
1.1.2. Stratification of HNSCC status 
 Currently many cancer treatment strategies utilize a genomic or proteomic component to 
stratify patients based on their genetic markers to approach treatment in a targeted-manner rather 
than using more general cytotoxic agents. For example breast cancer can be stratified based on 
HER2 expression, with HER2 positive tumors responding favorably to treatment with 
trastuzumab.
27
 In melanoma the presence of the V600E BRAF mutation is a predictive marker of 
BRAF inhibitor treatment with the majority of patients receiving such therapy experiencing a 
dramatic initial response and can therefore be used to stratify individuals possessing this 
mutation for treatment with vemurafinib and dasatinib.
28,29
 Finally, for non-small cell lung 
cancer (NSCLC), treatment is informed based on the mutational status of EGFR, with gefitinib 
and erlotinib being used for either exon19del deletion or an L848R missense mutation and the 
drug osimertinib being used for individuals possessing a T790M EGFR mutation, a mutation that 
confers resistance to gefitinib and erlotinib.
30 
The only stratification made in HNSCC to date is that of Human Papillomavirus (HPV) 
status with approximately 25% of HNSCC specimens containing HPV genomic DNA.
31
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Generally those cancers that are HPV positive respond more favorably to radiotherapy and see a 
significantly better 5-year survival rate than HPV negative individuals (80% vs. 20%).
32-35
 In the 
last decade, EGFR has been explored as a potential target in head and neck cancer. 
Overexpressed in up to 90% of cases,
36-38
 EGFR targeted therapy has seen the approval of 
cetuximab for HNSCC, the first new drug approved for use in HNSCC cancer in 45 years.
39,40
 
However, oncogenic signaling pathways still persist after use of cetuximab, which allow for the 
incidence of distant metastases and local-regional failure. Also despite its nearly ubiquitous 
expression in HNSCC, there is no evidence to date that EGFR expression levels can predict an 
individual patient’s response to EGFR targeted therapy making it less useful for prioritizing 
patient treatment.
39,41
 Being able to stratify these HPV-negative HNSCC tumors according to a 
genetic biomarker that could be used to predict individual’s response to treatment in a reliable 
way remains an important step on the path to informing treatment strategy and improving on a 
grave prognosis that has remained stagnant over the last several decades. 
 
1.2. Potential of NQO1 therapy in HNSCC 
 
1.2.1. Localization of NAD(P)H:quinone oxidoreductase 1 
NAD(P)H:quinone oxidoreductase 1 (NQO1) is a dimeric flavoprotein involved in the 
detoxification of xenobiotics and associated with protection against mutagenesis and 
carcinogenesis.
42,43
 NQO1 is a predominantly cytosolic protein with ~90% being found in the 
cytoplasm,
44
 but can also be found in the endoplasmic reticulum,
45
 mitochondria,
46
 Golgi body
47
 
and nucleus of cells.
48
 This enzyme is expressed in low levels in normal tissue; however, in 
certain epithelial cells expression is elevated.
49
 This includes respiratory, breast duct, and thyroid 
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follicle epithelium, the epithelial lining of the colon, and corneal and lens epithelia. Detectable 
expression is also seen in vascular endothelium, such as the lining of the aorta and capillary 
endothelium. Adipocytes from the lung, breast, ovary and colon, parasympathetic ganglion in the 
gastrointestinal tract, and the optic nerve and nerve fibers also stain positively for NQO1. There 
is minimal expression in hepatic tissues with only trace levels being detected via immunoblot 
analysis.
49 
 
1.2.2. Genetic regulation of NQO1 
The NQO1 gene itself is 20 kb and consists of 6 exons and 5 introns and contains several 
cis-activating transcriptional activators including an antioxidant response element (ARE) and a 
xenobiotic response element (XRE).
50-54
 As their names imply, these elements regulate gene 
expression in response to antioxidants or xenobiotics to protect cells against free radical damage, 
oxidative stress and neoplasia. NQO1 expression is under the control of the transcription factor 
Nrf2, which with its repressor KEAP1 comprise one of the major signaling cascades for stress 
response.  Under normal conditions KEAP1 is complexed with Nrf2 in the cytoplasm but upon 
exposure to antioxidants, Nrf2 is released from Keap1, translocates to the nucleus, and binds 
ARE to activate gene expression of NQO1.
55-60 
NQO1 has two characterized polymorphisms, NQO1*2 and NQO1*3. The NQO1*2 
polymorphism is more commonly present in ~4% of Caucasians and ~20% of Asian 
populations.
42,43,61-63
 The single point nucleotide polymorphism consists of a base substitution of 
cytosine to thymidine at position 609 of the cDNA sequence. This results in a proline to serine 
substitution in the protein that appears to cause a change in the enzyme conformation leading to a 
decrease in FAD binding affinity, loss of enzyme activity and an overall less stable protein that is 
5 
 
broken down in 1.2 h by the ubiquitin proteasomal pathway (UPP). Some studies suggest that 
individuals expressing this polymorphism have a higher risk of developing cancer while others 
suggest that this risk is small if present at all.
61,62
 The second NQO1 polymorphism, NQO1*3, is 
less common and less well studied.
64,65
 It results in a cytosine to thymidine base substitution at 
position 465 in the cDNA which effectively increases alternative splicing of the NQO1 gene 
leading to a decreased expression of the full protein. Any individuals expressing either of these 
NQO1 variants would not be expected to derive any benefit from an NQO1 targeted therapy. 
 
1.2.3. Overexpression of NQO1 in cancer 
NQO1 is expressed in a variety of solid human tumor types, predominantly those of 
epithelial origin.
66
 NQO1 levels in these solid tumors tend to be 5- to 20 –fold higher than 
associated normal tissue and the reason for this vast overexpression of NQO1 in solid tumors is 
still not clear. This overexpression phenomenon has been observed for a wide variety of solid 
tumors
49,67-90
 including those in the breast,
49,67-69
 lung,
49,68-76
 pancreas,
77-80
 prostate
81
 and head 
and neck.
71,82
 Furthermore, this enzyme has been implicated for its importance in maintaining 
oxidative homeostasis in the tumor microenvironment
56
 and depletion of NQO1 in these cells 
resulted in suppressed cell proliferation and tumor growth.
91 
 
1.2.4. Mechanism of NQO1 
NQO1 is an obligatory two electron reductase. Able to catalyze the two electron 
reduction of a variety of quinone, quinoneimines, azoaromatic and nitro aromatic 
compounds,
42,92,93
 this normal function of NQO1 helps to detoxify these compounds through 
formation of a stable hydroquinone which can be conjugated (to glutathione, sulfate or glucose), 
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excreted from the cell and eliminated (Fig. 1.1). This detoxification process prevents one-
electron mediated reduction processes from acting on these molecules, which would cause 
formation of a highly reactive semiquinone that in turn would undergo reduction-oxidation 
(redox) cycling producing high levels of toxic reactive oxygen species (ROS).
92,93
 It also serves 
as a detoxification enzyme through its ability to scavenge ROS through generation of antioxidant 
forms of alpha tocopherol
94
 and other endogenous quinones (Fig. 1.1).
95 
 
Figure 1.1. Normal detoxification and antioxidant mechanisms of NQO1. 
 
1.2.5. Prognostic implications of NQO1 expression 
NQO1 expression is typically higher in those with advanced stage tumors than early stage 
and in tumors that have metastasized to the lymph nodes. Tumors expressing high levels of 
NQO1 typically have a graver prognosis than their low NQO1 expressing counterparts.
67,75,83-85
 
Due to the increased NQO1 expression in larger, late stage tumors it is likely that either NQO1 
overexpression may confer a drive to grow, invade and metastasize or that the increased NQO1 
expression is simply due to the increased oxidative cellular environment which induces 
upregulation of the enzyme that maintains homeostasis. 
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1.3. NQO1 bioactivatable compounds 
While there have been many reports of anticancer agents that mediate their effects 
through NQO1-bioactivation,
96-101
 there are currently only two true compounds that exert their 
cytotoxic effects through NQO1-dependent means,
102,117
 β-lapachone (β-lap) and 
deoxynyboquinone (DNQ) (Fig 1.2). β-lap has demonstrated significant cytotoxicity in lung103-
105
 and breast
102,105-110
 cancer cell lines, as well as in vivo mouse models.
103,111
 Currently β-lap 
(ARQ761) is in clinical trials (NCT01502800 and NCT02514031). 
 
Figure 1.2. Structures of NQO1 bioactivatable compounds (a) β-lapachone and (b) 
deoxynyboquinone. 
 
1.3.1. Mechanism of NQO1 bioactivatable compounds 
 The classical mode of an anticancer agent and enzyme is for the anticancer molecule to 
bind in some form to the enzyme and inhibit its activity. β-lapachone and DNQ are unique in that 
instead of inhibiting the activity of NQO1 they are actually substrates for the enzyme.
104,112
 They 
are able to hijack the natural function of NQO1 in order to induce their cytotoxic effects. These 
molecules undergo the two electron reduction mediated by NQO1; however, unlike other 
quinones these two compounds do not form a stable hydroquinone. Instead these hydroquinones 
rapidly react with molecular oxygen present in the cell to generate a semiquinone intermediate 
8 
 
through release of ROS that can then react with another molecule of oxygen to form a second 
molecule of ROS and regenerate the parent quinone, ready to be processed again (Fig. 1.3). It is 
through this redox cycle and ROS generation that β-lap and DNQ exert their cytotoxic 
mechanism.  This process is catalytic and generates ≥ 60 mol of ROS within one minute.106,108  
 
Figure 1.3. DNQ exerts cytotoxic mechanism of action through NQO1-mediated redox cycling. 
 
The rapid generation and large quantities of superoxide leads to DNA base damage and 
single strand breaks. This leads in turn to significant PAR formation and drastic reduction in 
NAD+ and ATP levels due to hyperactivation of PARP-1, which is recruited to the damage site 
and attempts to repair those breaks. Hyperactivation of PARP-1 leads to a PARP-1-dependent 
mode of cell death known as parthanatos.
108,113-116 
 
1.3.2. Comparison of NQO1 bioactivatable compounds 
In head to head experiments comparing putative NQO1-activated anticancer agents, DNQ 
demonstrated superiority over mitomycin C and RH1 (both of which were shown not to be 
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substrates for NQO1), streptonigrin and β-lapachone.117 DNQ as an in vitro substrate for NQO1 
was processed 9 times faster than β-lap which was the next best substrate.117 The ability NQO1 
to process DNQ was highly efficient and approached the diffusion controlled limit.
117
 Similarly 
in head-to-head cell culture experiments DNQ was 10-100 fold more potent in two different cell 
lines (A549, a lung adenocarcinoma cell line, and MiaPaCa2, a pancreatic cancer cell line). 
Additionally DNQ has a larger therapeutic window, extended hepatic stability and dramatically 
longer half-life in mice than β-lap112 making it the current gold standard for NQO1-mediated 
anticancer therapy. Recently studies have shifted from DNQ to a derivative isobutyl-
deoxynyboquinone (IB-DNQ), which possesses similar catalytic and cytotoxic profiles to 
DNQ,
117
 but is more water soluble,
117,118
 and more tolerated in vivo.
119,120
 Therefore IB-DNQ 
provides an optimal candidate for evaluating the effectiveness of NQO1-targeted therapy in 
HNSCC. 
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Chapter 2. IB-DNQ for head and neck cancer 
 
Portions of this Chapter are reprinted with permission from Lundberg, A.P.; Francis, J.M; Pajak, 
M.; Parkinson, E.I.; Wycislo, K.L.; Rosol, T.J.; Brown, M.E.; London, C.A.; Dirikolu, L.; 
Hergenrother, P.J.; Fan, T.M. Invest. New Drugs 2017, 35, 134-144. 
 
2.1. FOSCC as model of HNSCC 
 Experimental model systems used for testing novel anticancer compounds have relied on 
murine tumor models, yet greater than 90% of oncology agents demonstrating robust activity in 
mouse models fail to become approved drugs for humans.
1
 This low translational success rate of 
novel drugs can be partially ascribed to the limitations of murine tumor models to accurately 
predict drug efficacy in human patients.
2-5
 The inclusion of pets with naturally occurring cancers 
has recently emerged as a potential complementary development strategy for improving the 
prediction of a drug’s potential for clinical success or failure.6-8  
 Many cancers arising naturally in companion animals share genetic, molecular and 
clinical similarities to the human disease.
9-11
 Specifically, feline oral squamous cell carcinoma 
(OSCC) might serve as an appropriate epithelial malignancy for the advancement of NQO1 
bioactivatable drugs, such as IB-DNQ, based on shared cancer biology between domestic felids 
and humans diagnosed with HNSCC.
12,13 
 Feline OSCC is the most common oral tumor in cats and despite medical advances in 
cancer treatment remains associated with a grave prognosis with cats succumbing to local 
disease progression within 2-4 months of diagnosis, regardless of therapy.
14,15
 Therefore there is 
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a need to identify novel and effective treatments for OSCC,
16
 and advances made with NQO1-
mediated therapy in these patients should be directly translatable to their human counterparts. 
 
2.1.1. NQO1 expressions by OSCC cell lines and spontaneous tumors 
 NQO1 expression in feline cell lines has not been investigated previously and as there are 
no NQO1 antibodies designed specifically for feline NQO1, thus other NQO1 antibodies must be 
used. Feline cross-reactivity of anti-NQO1 antibody was confirmed by Western blot analysis 
(Fig 2.1). The 3 immortalized feline OSCC cell lines variably expressed NQO1 protein 
confirmed by Western blot analysis and immunohistochemistry (Fig. 2.2a & b). The expression 
of NQO1 was robust in the SCCF1 and SCCF2 cell lines, while the SCCF3 cell line had the 
lowest expression. NQO1 expressions correlated with enzymatic activities with SCCF1 and 
SCCF2 exerting comparable functional activities of 1719.7 ± 462.6 nmol/min/μg and 1685.0 ± 
967.4 nmol/min/μg , respectively. Concordant with reduced NQO1 expression, the SCCF3 cell 
line possessed approximately 1-log order less NQO1 activity compared to either SCCF1 or 
SCCF2, measuring 126.3 ± 53.8 nmol/min/μg  (p<0.05, Fig 2.2c).  In naturally occurring feline 
OSCC samples, 46 out of 50 tumors were evaluable for NQO1 staining. The majority of tumors 
(40/46) demonstrated some degree of NQO1 expression, with categorical staining intensities 
being 26.1% (+++), 32.6% (++) and 28.3% (+). Six tumors, accounting for 13% of samples, 
were completely devoid of any NQO1 staining (Fig. 2.3). Analogous to feline OSCC tumors, the 
majority of human OSCC tissues (43/60) expressed NQO1 with categorical staining intensities 
being 21.7% (+++), 23.3% (++), 25% (+) and 30% negative (Fig 2.3). 
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Figure 2.1. Confirmatory Western blot for feline cross reactivity of anti-NQO1 antibody. A549, 
a lung cancer cell line, and HEK293, a BLANK cell line, were used as positive and negative 
controls respectively. β-actin levels were used as loading controls. 
 
 
Figure 2.2. In 3 feline OSCC immortalized cell line, variable NQO1 protein expression detected 
by (a) Western blot and (b) immunohistochemistry; human positive (A549) and negative  
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Figure 2.2. (cont,) (HEK293) control cells. Confirmation of (c) variable NQO1 enzymatic 
activities correlate with protein expressions. Data presented as average ±SD; *denotes p < 0.05. 
 
 
Figure 2.3. Forty-six and sixty spontaneous feline- and human-derived OSCC samples, 
respectively, evaluated for NQO1 protein expression by immunohistochemistry. Representative 
images and tabulated summary of categorical NQO1 intensity grading relative to positive control 
(A549). Scale bar = 100 μm. 
 
2.1.2. In vitro cytotoxicity 
 
2.1.2.1. In vitro IB-DNQ cytotoxicity in FOSCC cell lines  
 Based upon the established mechanism of NQO1-mediated bioactivatable drugs to induce 
cancer cell death,
17-20
 the potency of IB-DNQ against the 3 feline OSCC cell lines was explored. 
Dose response curves of SCCF1, SCCF2 and SCCF3 to IB-DNQ mediated cytotoxicity 
correlated with enzymatic activities (Fig 2.4), with IB-DNQ demonstrating greater cytotoxic 
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potency against SCCF1 and SCCF2 cell lines (IC50 0.37 ± 0.14 μM and 0.12 ± 0.10 μM, 
respectively), and less against the SCCF3 cell line (IC50 2.11 ± 0.51 μM). Induction of 
cytotoxicity by NQO1-mediated activity was confirmed by a reduction in cell death and right 
shifting of the dose response curve when cells were co-incubated with IB-DNQ and the NQO1 
inhibitor dicoumarol. Consistent with previous results,
18
 in comparison with β-lapachone, IB-
DNQ demonstrates a 5-10 fold increase in cytotoxic potency against SCCF1 and SCCF2 cell 
lines and approximately a 2-fold increase in potency against the SCCF3 cell line. The IC50 values 
for β-lapachone against SCCF1, SCCF2 and SCCF3 were 2.87 ± 0.51 μM, 1.39 ± 0.28 μM, and 
3.11 ± 0.49 μM, respectively. 
 
Figure 2.4. Dose-dependent cytotoxic effects of IB-DNQ (a-c) and β-lapachone (d-f) in 3 
immortalized feline OSCC cell lines, in the presence or absence of dicoumarol (25 μM).  
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Figure 2.4. (cont.) Increased susceptibility of (a/d) SCCF1 and (b/e) SCCF2 cell lines to NQO1 
mediated cytotoxicity predicted by correlative NQO1 enzyme activity levels. Attenuated NQO1 
mediated cytotoxicity in (c/f) SCCF3 cell line based upon reduced NQO1 expression and 
activity. 
 
2.1.2.2. Sequential exposure to in vitro IB-DNQ induces cumulative cytotoxicity 
 Often in the drug development process, a disconnect exists between a compound’s 
potency in cell culture and its potency in vivo which can lead to failure of the compound. 
Relevant compound concentrations and duration of compound exposure are two variables that 
influence cell culture potency and that can be different in vivo. Additionally, the majority of cell 
culture experiments involve a single exposure to compound, a contrast from the multiple 
administrations typically encountered in a clinical setting. Therefore a set of cell culture 
experiments were designed in which cells would be exposed to, in repeated, short bursts, 
compound based on preliminary pharmacokinetic data from Section 2.1.3. These experiments 
would mimic in vivo conditions and potentially be a more accurate predictor of compound 
potency in vivo.  
 Sequential and repeated exposure to IB-DNQ for time durations (1h) and at 
concentrations (≤ 3.0 μM) likely to be achievable in vivo were assessed in the SCCF1 cell line. 
At the lowest concentration of IB-DNQ (0.1 μM), no significant loss in cell viability was 
identified regardless of the number of sequential 1-h daily pulse exposures (Fig 2.5). On the 
contrary, substantive increases in cytotoxicity were documented following exposure to IB-DNQ 
at 0.4 μM, with approximately 60-65% death occurring after 1 or 2 sequential, treatments and 
greater than 90% loss of viability following 5 consecutive daily exposures to IB-DNQ (Fig X). 
At the highest concentration of IB-DNQ (3.0 μM), near quantitative cytotoxicity was achieved 
following ≥ 2 consecutive treatments, with 96% cell death being induced following sequential 
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IB-DNQ exposure (Fig 2.5). The induction of cytotoxicity as a function of IB-DNQ 
concentration and sequential exposure is summarized in Table 2.1. 
 
Figure 2.5. Repeated exposure of SCCF1 cells to IB-DNQ for biologically-achievable time 
durations (60 min) induces cytotoxicity in a dose dependent manner with SRB viability assay. 
(a/d) No observed cumulative cytotoxicity observed with the lowest concentration of IB-DNQ, 
however, concentrations of 0.4 μM (b/d) and 3.0 μM (c/d) exert substantive to profound 
cytotoxicity after ≥ 2 sequential IB-DNQ exposures. Negative control wells (red outline) with no 
cells, positive control wells (green outline) with untreated cells, and sequential treated wells 
(blue outline) with IB-DNQ exposed cells. Data represented as average ± SD; **p < 0.01. 
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Table 2.1. Cytotoxicity following sequential exposure to IB-DNQ 
IB-DNQ  
Number of Treatments 
0.1 μM  
% Viable 
0.4 μM  
% Viable 
3.0 μM  
% Viable 
0 100 ± 0 100 ± 0 100 ± 0 
1 96.0 ± 14.4 39.8 ± 16.0** 22.9 ± 13.5** 
2 93.9 ± 20.4 36.4 ± 32.2** 3.7 ± 2.5** 
3 84.2 ± 26.5 15.9 ± 10.9** 1.9 ± 0.5** 
4 77.3 ± 36.2 9.9 ± 7.8** 1.4 ± 0.4** 
5 75.8± 49.3 8.0 ± 5.4** 1.5 ± 0.6** 
Data expressed as average ± SD 
 
Sequential and repeated exposure to IB-DNQ for time durations (1h) and at 
concentrations (≤ 3.0 μM) likely to be achievable in vivo were next assessed in the SCCF3 cell 
line (Fig 2.6). Due to the decreased expression of NQO1 in this cell line it was expected that the 
effect of sequential exposure to IB-DNQ would be attenuated. At the lowest concentrations of 
IB-DNQ, neither 0.1 μM nor 0.4 μM showed any significant loss in cell viability regardless of 
the number of sequential 1-h daily pulse exposures. At the highest concentration of IB-DNQ (3.0 
μM), initially there appeared to be no response to IB-DNQ, but upon subsequent exposures to 
IB-DNQ, an incremental loss in cell viability was identified with approximately 50% cell death 
occurring at the end of 4 sequential exposures. Additional studies that incorporate a higher 
number of exposures to determine whether this trend continues or if after a certain number of 
exposures the cells would develop resistance to IB-DNQ would help inform treatment protocols 
in the clinic. The induction of cytotoxicity as a function of IB-DNQ concentration and sequential 
exposure in SCCF3 cells is summarized in Table 2.2. 
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Figure 2.6. Repeated exposure of SCCF3 cells to IB-DNQ for biologically-achievable time 
durations (60 min) induces cytotoxicity in a dose dependent manner with SRB viability assay. 
(a,b,d) No observed cumulative cytotoxicity observed with the lowest concentrations of IB-
DNQ, however, concentrations of 3.0 μM (c/d) exert incremental cytotoxicity after ≥ 2 
sequential IB-DNQ exposures. Negative control wells (red outline) with no cells, positive control 
wells (green outline) with untreated cells, and sequential treated wells (blue outline) with IB-
DNQ exposed cells. N=1. 
 
Table 2.2. Cytotoxicity following sequential exposure to IB-DNQ in SCCF3 cells 
IB-DNQ  
Number of Treatments 
0.1 μM  
% Viable 
0.4 μM  
% Viable 
3.0 μM  
% Viable 
0 100  100  100  
1 104 103 101 
2 97 94 82 
3 101 99 71 
4 95 96 58 
N=1 
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From preliminary pharmacokinetic studies in healthy felines it became apparent that, in 
contrast to mice, IB-DNQ was short lived in vivo. Therefore a similar sequential exposure 
experiment was performed in NQO1 expressing SCCF1 cells in order to target the minimum 
incubation time for IB-DNQ to exert cytotoxicity (Fig. 2.7). SCCF1 cells were incubated with a 
concentration of 3.0 μM IB-DNQ for a 15 minute window every 24 h for up to four exposures. 
Given this minimal time frame, it was surprising to see drastic loss in cell viability within two 
exposures up to 60% cell death similar to that seen with the longer 1-h incubation time. At the 
end of 4 IB-DNQ exposures less than 15% of cell were still viable. The induction of cytotoxicity 
upon 15 min of exposure as a function of IB-DNQ concentration and sequential exposure is 
summarized in Table 2.3 
 
Figure 2.7. Repeated exposure of SCCF1 cells to IB-DNQ for extremely short time durations 
(15 min) induces cytotoxicity in a dose dependent manner with SRB viability assay. (a/b) a 
concentration of 3.0 μM  exerts substantive to profound cytotoxicity after ≥ 2 sequential IB-DNQ 
exposures. Negative control wells (red outline) with no cells, positive control wells (green 
outline) with untreated cells, and sequential treated wells (blue outline) with IB-DNQ exposed 
cells. N=1. 
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Table 2.3. Cytotoxicity following 15 min sequential exposure to IB-DNQ 
IB-DNQ  
Number of Treatments 
3.0 μM  
% Viable 
0 100  
1 78 
2 40 
3 23 
4 14 
N=1 
 
2.1.3. Pharmacokinetics of IB-DNQ in healthy cats 
 Pharmacokinetics were derived from 4 healthy research cats, following single-dose, IV 
administration at 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg; average peak plasma concentration levels 
were 1227.4 ± 273.3 ng/mL (3.8 ± 0.8 μM), 1731.3 ± 163.5 ng/mL (5.3 ± 0.5 μM), and 3426.3 
ng/mL ±1249.7 (10.5 ± 3.8 μM), respectively (Fig 2.8a). Terminal elimination half-life at 0.5 
mg/kg, 1.0 mg/kg and 2.0 mg/kg IV was 19.5 ± 2.2 min, 30.0 ± 17.4 min, and 115.8 ± 90.7 min, 
respectively. Orally dosed IB-DNQ at 1.0 mg/kg achieved peak plasma concentrations and oral 
bioavailability of 94.7 ± 52.1 ng/mL and 13.8%, respectively (Fig 2.8b). Full pharmacokinetic 
parameters for IB-DNQ administered IV and PO are detailed in Tables 2.4 and 2.5. 
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Figure 2.8. Pharmacokinetic profile of (a) intravenous IB-DNQ dosed at 0.5 mg/kg, 1.0 mg/kg, 
and 2.0 mg/kg as an aqueous solution in HPβCD, and (b) oral IB-DNQ dosed at 1.0 mg/kg via 
gavage as an oral slurry in HPβCD. Data represented as average ± SD. 
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Table 2.4. Pharmacokinetic parameters of IB-DNQ following IV administration 
 
0.5 mg/kg IV 1.0 mg/kg IV 2.0 mg/kg IV 
AUC0-inf (ng x min/mL) 44,223.5 ± 6969.2 55,732.6 ± 6043.8 113,064.4 ± 46844.1 
K10-HL (min) 5.7 ± 0.4 8.2 ± 3.7 13.7 ± 1.5 
α (1/min) 0.2 ± 0.0 0.1 ± 0.1 0.1 ± 0.0 
β (1/min) 0.0 ± 0.0  0.0 ± 0.0  0.0 ± 0.0  
t1/2 α (min) 4.3 ± 0.1 6.2 ± 4.1 10.9 ± 1.5 
t1/2 β (min) 19.5 ± 2.2 30.0 ± 17.4 115.8 ± 90.7 
A (ng/mL) 483.4 ± 1068.6 4659.9 ± 1628.0 5582.9 ± 2395.2 
B (ng/mL) 507.3 ± 202.0 813.8 ± 838.2 198.5 ± 162.5 
Cmax (ng/mL) 1227.4 ± 273.3 1731.3 ± 163.5 3426.3 ± 1249.7 
Cl (mL/min) 40.3 ± 6.8 63.4 ± 7.0 73.9 ± 39.8 
AUMC0-inf (ng x min x min/mL) 577,057.8 ± 109,204.2 1,017022.9 ± 266,567.0 7,697,841.3 ± 8,839,491.6 
MRT (min) 13.0 ± 1.3 18.5 ± 5.6 57.7 ± 50.8 
Vss (mL) 524.5 ± 91.5 1189.9 ± 438.1 3409.0 ± 1857.8 
V2 (mL) 191.6 ± 34.3 430.5 ± 164.6 1956.2 ± 2043.2 
Cld2 (mL/min) 9.4 ± 3.1 18.0 ± 9.4 13.5 ± 5.0 
Parameters derived from 4 research cats and expressed as average ± SD 
 
Table 2.5. Pharmacokinetic parameters of IB-DNQ following 1.0 mg/kg PO administration 
 1.0 mg/kg PO 
AUC (min*ng/mL) 7718.1 ± 3311.3 
K01_HL (min) 4.3 ± 2.4 
K10_HL (min) 54.5 ± 26.1 
CL_F (mL/min) 588.0 ± 424.4 
Tmax (min) 15.1 ± 8.7 
Cmax (ng/mL) 97.5 ± 51.8 
Parameters derived from 4 research cats and expressed as average ± SD 
 
2.1.4. Tolerability of IB-DNQ in healthy cats 
 To assess the tolerability of IB-DNQ, we evaluated hematologic, non-hematologic, and 
clinical observational toxicities associated with each administration. Prior to IB-DNQ 
administration, baseline CBCs and chemistry panels were performed and then repeated at 1, 3, 7 
and 14 days post-treatment. No clinically meaningful hematologic or non-hematologic toxicities 
were documented throughout the duration of study. Additionally, each feline subject was 
monitored for the development of acute clinical side effects peri-infusion and post-infusion (30 
min). The most notable observed clinical abnormalities were ptyalism and tachypnea in all cats 
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following 2.0 mg/kg IV, with clinical symptoms resolving within 30 min of infusion completion. 
At 1.0 mg/kg, cats exhibited transient tachypnea in the absence of ptyalism. Administration at 
0.5 mg/kg IV and 1.0 mg/kg PO did not elicit any observable symptoms. Long-term follow-up 
for an additional 9 months confirmed the absence of delayed-onset clinical, hematologic, and 
non-hematologic toxicity, further supporting an acceptable safety profile. 
 
2.1.5. Assessment of off-target systemic oxidative injury 
 The potential for non-specific systemic oxidative injury as a consequence of IB-DNQ 
exposure was assessed by quantifying changes in serum 8-OHdG. At 0.5 mg/kg IV, pre-
treatment and post- treatment concentrations of serum 8-OHdG were 9.0 ± 2.1 ng/mL and 8.1 ± 
1.7 ng/mL, respectively (p = 0.3). At the highest dosage of IB-DNQ (2.0 mg/kg IV), a reduction 
in serum 8-OHdG concentrations were detected between pre-treatment (9.2 ± 2.2 ng/mL) and 
post-treatment (7.8 ± 2.0 ng/mL) sampling (p = 0.02) 
 
2.2. Summary of pre-clinical work 
 Given the mechanism of NQO1 bioactivatable agents, solid tumor histologies 
overexpressing NQO1 would be expected to be most responsive to IB-DNQ. Overexpression of 
NQO1 has been documented across a multitude of epithelial cancers arising from tissues of the 
gastrointestinal, reproductive and respiratory systems.
21-23
 Relevant to the current investigation, 
NQO1 is shown to be overexpressed by malignantly transformed squamous cell epithelium 
arising from the uterine cervix and oral cavity.
24,25
 Specific to OSCC, overexpression of NQO1 
has been identified in 45% of primary tumor samples, and demonstrated the feasibility of 
targeting NQO1 with β-lapachone in combination with ionizing radiation.24 Complementing 
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these findings, results from our study further confirms the suitability of OSCC as a tumor 
histology that might benefit from NQO1 bioactivatable therapies as 45% (27/60) of human-
derived tissue microarray samples demonstrated robust (++ or +++) NQO1 expression. 
Importantly, we provide new information that supports the inclusion of feline OSCC as a 
relevant comparative tumor model for exploring NQO1-mediated therapies based upon the 
identification of intense (++ or +++) NQO1 expression on 59% (27/46) of naturally-occurring 
feline OSCC tumor samples. 
 Multiple studies have demonstrated that quinone-containing compounds, such as β-
lapachone and DNQ, have the capacity to serve as NQO1 substrates that generate ROS thereby 
inducing cancer cell death.
6,18,26,27
 Despite the exertion of selective anticancer cytotoxicity, the 
clinical translation of these agents has been hindered by their modest activity, unfavorable 
pharmacokinetics or narrow biologic tolerability.
20
 As such, impetus exists for the rational 
development of newer NQO1 substrates with improved potency, pharmacokinetics, and 
biocompatibility. Regarding potency, IB-DNQ exerted 5- to 10-fold increase in cytotoxicity in 
robust NQO1 expressing OSCC cell lines in comparison to β-lapachone. Importantly, IB-DNQ 
exerted substantive cytotoxicity in OSCC cell lines at biologically relevant durations of drug 
exposure (1h) and concentrations (0.4 μM, or equivalent 130 ng/mL) readily and safely 
achievable in healthy research cats receiving IB-DNQ dosages ≥1.0 mg/kg IV. The melding of 
classical in vitro cell-based experiments with necessary in vivo modeling justifies continued 
development of IB-DNQ for translational applications. 
 Biocompatibility of investigational agents is essential for successful translational 
applications, and in the context of NQO1 bioactivatable molecules, excessive or systemic 
production of reactive oxygen species has potential to induce global endothelial cell injury, 
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inflammation, and consequent end-organ failure. Prior research with DNQ, the parent compound 
of IB-DNQ, demonstrated that one mole of DNQ in the presence of NQO1-epxressing cancer 
cells can generate greater than 60 mol of superoxide per minute.
20
 When administered to mice, 
both DNQ and β-lapachone possess narrow ranges for biologic compatibility and drug exposures 
predicted to exert anticancer activities closely approximate similar concentrations that induce the 
formation of methemoglobinemia,
20
 a biomarker of red blood cell oxidative stress. Given the 
potential for off-target oxidative injury, it is scientifically judicious to evaluate NQO1 
bioactivatable molecules in model systems that are sufficiently sensitive for the detection of 
oxidative stress. In the current study, we employed the inclusion of healthy felines as a model 
system to test the biocompatibility of IB-DNQ. The felid species is uniquely vulnerable to global 
oxidative injury given the high number of free sulfhydryl groups on their hemoglobin allowing 
for identification of oxidative stress through the detection of Heinz bodies and resultant 
hemolytic anemia.
28
 Our findings suggest that IB-DNQ is highly biocompatible in the felid 
species, with clinically negligible hematologic (Heinz body anemia) and non-hematologic 
toxicities following repeated systemic exposures to IB-DNQ predicted to exert anticancer 
activities. Further confirmation of IB-DNQ’s oxidative tolerability in healthy felines was 
supported by the serial quantification of hydroxydeoxyguanosine (8-OHdG), a specific 
biomarker for DNA oxidation. In all research felines, no increases in serum 8-OHdG 
concentrations were identified 24-h following 0.5 mg/kg and 2.0 mg/kg IV IB-DNQ 
administration. 
 Collectively, the cell-based and live animal data derived from a uniquely sensitive 
species presented in this study strongly supports continued development of IB-DNQ as a novel 
and biocompatible drug for the treatment of NQO1 expressing cancers, such as OSCC in both 
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felids and human cancer patients. The future purposeful inclusion of companion animals as a 
naturally-occurring tumor model holds promise for expediting the drug development pathway for 
NQO1 bioactivatable molecules, and might provide intriguing and relevant findings to support 
the tractability of IB-DNQ, as a single agent or in combination with other cytotoxic modalities, 
for continued drug development and clinical translation. 
 
2.3. Clinical evaluations of IB-DNQ in OSCC patients 
 
2.3.1. Single agent efficacy in patient cats with OSCC 
Three felines with histologically-confirmed FOSCC were recruited for a small pilot study 
to evaluate the tolerability and anticancer activities of IB-DNQ administered IV at a dosage of 
1.0 mg/kg for 3-4 consecutive treatments over a 4-6 week period.  Originally the pilot study was 
designed to for patients to receive 3 consecutive treatments of 1.0 mg/kg IV IB-DNQ over a six 
week period with two weeks in between treatment times, however, it was determined that 
research cats were able to tolerate dosing every week and even up to five consecutive days. 
Therefore, since OSCC rapidly progresses in felines and a more accelerated dosing regimen was 
well tolerated, after completion of the first cat in the study, the design was modified to 
administration once a week for up to four treatments. Prior to treatment, computed tomography 
(CT) scans were performed in all cats to establish the initial tumor burden (Fig. 2.9). Tumor 
samples were collected from each cat and stained for NQO1 expression by IHC and scored 
similar to HNSCC and FOSCC microarray scoring (Fig. 2.9).  One week after the culmination of 
treatments, CT scans were repeated in the patient cats to assess the effectiveness of IB-DNQ 
treatment.  The result of 1.0 mg/kg IV IB-DNQ in the small cohort of cats was 1 partial response 
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(43% reduction in tumor cross sectional area), 1 stable diseased (5% increased) and 1 
progressive disease (82% increases).  The clinical responses to IB-DNQ correlate well with the 
expression of NQO1 in the tumor biopsies (Fig 2.9). 
 
Figure 2.9. Clinical responses to single agent IB-DNQ. For (a-c) the pre-treatment CT scan (far 
left), the post-treatment CT scan upon the completion of 3-4 doses 1 mg/kg IV IB-DNQ (middle) 
and the IHC tumor biopsy evaluated for NQO1 expression. Patients’ responses to treatment 
correlate well to tumor expression NQO1 (a) High expression; partial response (b) medium 
expression; stable disease (c) low expression; progressive disease. 
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2.3.2. Combination therapy in patient cats with OSCC 
   
2.3.2.1. In vitro responses of NQO1 expression to ionizing radiation 
IHC staining of HNSCC and FOSCC tumors showed that roughly 25% of head and neck 
tumors express NQO1, albeit at low levels that should not respond to single agent IB-DNQ.  
Recent studies have shown that NQO1 expression can be induced in response to ionizing 
radiation
29-31
 and other methods.
32-35
  As combined treatment modalities involving radiation are 
commonly used in HNSCC, a combined IR + IB-DNQ therapy may allow for greater response in 
the 50% of tumors expressing medium to high levels of NQO1 as well allowing therapeutic 
access to the other 25% of tumors that express NQO1, but not at levels required for single agent 
IB-DNQ efficacy.  SCCF3 (low NQO1 expressing feline OSCC, Fig. 2.2) cells were exposed to 
IR at doses of 2, 4, 6 or 8 Gy and monitored for NQO1 expression (Fig 2.10a) and activity (Fig 
2.10b) for up to 24 h post radiation exposure.  The levels of NQO1 expression appear elevated 4- 
h post-radiation and remains elevated 24-h post-radiation.  NQO1 activity shows a similar 
upregulation, showing maximal peak increase in response to 8 Gy radiation roughly 2-4 h post-
exposure.  Systemic administration of IB-DNQ 2-4 h after exposure to 8 Gy IR should be the 
optimal window for administration in order to maximize the potential cytotoxic response in 
medium and low NQO1 expressing tumors. 
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Figure 2.10. IR induced NQO1 expression as determined by (a) Western blot analysis and 
confirmed by (b) enzyme activity for 2-8 Gy over a 24-h period post-radiation. 
 
2.3.2.2. Combination efficacy in patient cats with OSCC 
Two felines with histologically-confirmed FOSCC were enrolled in a small pilot study to 
evaluate the tolerability and anticancer activities of IR and IB-DNQ combination therapy.  
Felines were exposed to 8 Gy IR and treated systemically with 1 mg/kg IV IB-DNQ 4 hours after 
radiation weekly for 4 consecutive treatments.  Initial tumor CTs and tumor biopsies were taken 
prior to treatment (Fig 2.11).  At the culmination of 4 treatments, follow-up CTs were taken to 
examine the effectiveness of the combination treatment (Fig 2.11). Both patients had observable 
reduction in tumor size with 42% reduction observed in the medium NQO1 expressing tumor 
and 45% reduction in the low NQO1 expressing patient.  The results in this small cohort of 
patients demonstrate that combination of IR and subsequent systemic IB-DNQ administration 
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can be applied clinically and is a potentially promising treatment modality for FOSCC, 
especially in those expressing low levels of IB-DNQ which are not expected to respond strongly 
to single agent IB-DNQ. 
 
Figure 2.11. Clinical responses to combination IR and IB-DNQ. For (a & b) the pre-treatment 
CT scan (far left), the post-treatment CT scan upon the completion of 4 doses 1 mg/kg IV IB-
DNQ (middle) and the IHC tumor biopsy evaluated for NQO1 expression. While both patients 
would be predicted to not respond favorably to single agent IB-DNQ based on tumor NQO1 
expression, both saw regression with combination IR and IB-DNQ. 
 
2.4. In vitro cytotoxicity in HNSCC cell lines 
 As discussed previously, sample primary tumors from human patients with HNSCC 
demonstrated a high prevalence of NQO1 expression. The expression of NQO1 was further 
evaluated in a panel of five HNSCC cell lines received from Dr. David A. Boothman (UT 
Southwestern) that had previously been reported to widely range in NQO1 expression levels. 
Western blot analysis of these cell lines were examined in relation to A549, a high NQO1-
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expressing non-small cell lung carcinoma cell line, and MDA-MB-231, a breast cancer cell line 
possessing a NQO1*2 polymorphism which results in the production of nonfunctional NQO1 
that is quickly degraded by the cell, as positive and negative controls respectively (Fig 2.12). 
NQO1 expression was highest in Detroit562 and FaDu cells. Intermediate expression levels were 
observed in MDA686LN cells and low levels were observed with the HN30 cell line. The 
JHU029 cell lines possessed no observable NQO1 expression. 
 
Figure 2.12. In 5 HNSCC immortalized cell lines, variable NQO1 protein expression detected by 
western blot; positive (A549) and negative (HEK293) control cells. β-actin used as loading 
control. 
.  
The potency of IB-DNQ was evaluated in JHU209, HN30, MDA686LN and FaDu in the 
presence or absence of 100 nM ES936, a mechanistic inhibitor of NQO1 (Fig. 2.13). Cells were 
exposed to IB-DNQ for a 2-h pulse in the presence or absence of a 1-h pretreatment with ES936. 
The cytotoxicity of IB-DNQ in the non-NQO1 expressing JHU029 cell line remained unchanged 
in the presence or absence of this specific inhibitor, 5.14 ± 0.02 μM and 4.57 ± 2.88 μM 
respectively. In HN30 cells with low NQO1 expression and MDA686LN cells with intermediate 
NQO1 expression, a three-fold protection from IB-DNQ cytotoxicity was observed in the 
presence of ES936 (3.7 ± 0.5 μM vs. 11.5 ± 1.1 μM for HN30 and 2.8 ± 0.3 μM vs. 7.7 ± 2.4 μM 
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for MDA686LN). IB-DNQ was most potent in FaDu cells (0.27 ± 0.03 μM), the cell line with 
the most robust NQO1 expression, and experienced a 35-fold protect by pre-incubation with 
ES936 (9.4 ±  1.2 μM). 
 
Figure 2.13. Dose-dependent cytotoxic effects of IB-DNQ in 4 immortalized HNSCC cell lines, 
in the presence or absence of ES935 (100 nM). Increased susceptibility of (a) FaDu, (b) HN30,  
(c) MDA686LN cell lines to NQO1 mediated cytotoxicity predicted by correlative NQO1 
enzyme expression levels. Attenuated NQO1 mediated cytotoxicity in (d) JHU029 cell line 
based upon reduced NQO1 expression. 
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2.5. Summary 
The identification of molecular aberrations specific to tumors provides the opportunity to 
develop selective and effective anti-cancer strategies. As such, efforts in cancer therapeutic 
research have focused intensely either on the discovery of new druggable targets or the 
development of better drugs that act upon known targets. In the current investigation, we 
generate data to advance therapeutic development through novel experimental therapeutics that 
act upon existing druggable targets. Specifically, the findings reported herein substantiate the 
continued development of IB-DNQ, a novel NQO1 bioactivatable molecule, for the treatment of 
OSCC, a NQO1 expressing tumor histology. To expedite the advancement of IB-DNQ towards 
translational applications in human oncology patients, we characterized the in vitro anticancer 
activities, and in vivo tolerability and pharmacokinetics of IB-DNQ in domestic felids, a species 
highly sensitive to oxidative injury and stress.
28,36,37
 Given that unacceptable drug toxicity and 
lack of activity remain major barriers along the road to successful new drug development, the 
promising cell-based cytoreductive activities in conjunction with the confirmed tolerability and 
predictable pharmacokinetics of IB-DNQ in a highly sensitive species and relevant comparative 
tumor model, improves confidence in the tractability of IB-DNQ as a novel anticancer agent for 
the treatment of human oncology patients. 
 
2.6. Materials 
Cell lines and reagents 
Three feline OSCC cell lines (SCCF1, SCCF2, SCCF3; provided by Thomas J. Rosol, the 
Ohio State University) were used in this study. Cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
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(100 IU/mL each). Cells were maintained at 37°C in 5% CO2. IB-DNQ was synthesized as 
previously described.
18
 For all in vitro experiments, IB-DNQ or β-lapachone (Sigma-Aldrich, St. 
Louis, MO) was reconstituted with 99.5% DMSO (Sigma-Aldrich, St. Louis, MO) to produce 10 
mM stock solution which was kept frozen at -80°C until needed. For in vivo experiments, IB-
DNQ was reconstituted to 1.0 mg/mL in 2-hydroxypropyl-B-cyclodextrin (HPβCD) (Sigma-
Aldrich, St. Louis, MO) and sterile water at a pH of 8.0-8.5 prior to administration. 
 
Antibodies 
Anti-NQO1 antibody (goat polyclonal; ab2346), anti-β actin antibody (mouse 
monoclonal; ab6276) and horseradish peroxidase (HRP) conjugated anti-mouse secondary 
antibody (ab6814) were purchased from Abcam (Abcam, Cambridge, MA) and anti-goat 
secondary antibody (SC-2020) was purchased from Santa Cruz Biotechnology (Santa Cruz 
Biotechnology, Dallas, TX). StrepTactin-HRP conjugate was purchased from Bio-Rad (Bio-Rad, 
Hercules, CA). Cross-reactivity of the anti-NQO1 antibody against feline tissues was validated 
by Western blot analysis and immunohistochemistry with the inclusion of known human positive 
(A549) and negative (HEK293) control cell lines purchased from American Tissue Culture 
Collection (Manassas, VA). 
 
Western Blot Analysis 
Cell lysate proteins were collected using a commercial reagent and provided protocol (M-
PER Assay, Thermo Scientific, Rockford, IL). For each cell line, 30 μg of protein were 
electrophoresed on a 4-20% SDS-PAGE gel and transferred to a nitrocellulose membrane. 
Membranes were blocked with Tris-Buffered Saline with Tween 20 (TBST) in 5% milk for 1 h 
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at room temperature. Western blot analysis was performed using the anti-NQO1 antibody at a 
concentration of 1:1000 in TBST with 5% milk. The membrane was washed 3 times with TBST 
and probed with the secondary antibody diluted (1:5000) in TBST with 5% milk. For anti-β-
actin, antibody dilution of 1:2000 and secondary antibody was used at a dilution of 1:5000. Blots 
were developed using a standard chemiluminescence detection kit (GE Healthcare Life Sciences, 
Pittsburgh, PA) and ChemiDoc XRS+ molecular imager system (Bio-Rad, Hercules, CA) with 
Image Lab Software (Bio-Rad, Hercules, CA). Relative protein expressions were adjusted 
against β-actin serving as a loading control. At least 2 independent experiments were performed. 
 
Immunohistochemistry 
Cell lines: Adherent cell cultures of OSCC and the human positive (A549) and negative 
(HEK293) control cell lines were collected, pelleted, and formalin fixed followed by 
resuspension in agarose gel to create an agarose-embedded cell pellet. Cell pellets were trimmed, 
processed and cut onto slides. Slides were treated and stained with the NQO1 antibody according 
to manufacturer recommendations, and counter stained with hematoxylin. Staining intensity for 
each OSCC cell line was compared with that of the positive control (A549). NQO1 staining 
intensity was scored categorically: (-) no staining; (+) light staining; (++) moderate staining; and 
(+++) intense staining. 
Tissue blocks and microarrays: Thirteen feline OSCC tissue blocks from the University 
of Illinois Veterinary Diagnostic Laboratory, a tissue microarray of 37 feline OSCC samples 
provided by Cheryl A. London and Megan E. Brown, the Ohio State University, and a 
commercially-available tissue microarray of 60 human OSCC samples (US Biomax) were 
assessed by immunohistochemistry for NQO1 expression. The staining intensity for each sample 
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was compared with the staining of the positive (A549) control using the previously described 
scoring system. 
 
NQO1 enzymatic activity assay 
NQO1 enzymatic activity was quantified with an activity assay (Abcam, Cambridge, 
MA, ab184867). Varying concentrations of OSCC protein from each cell line, in the presence or 
absence of an NQO1 inhibitor, (25 μM dicoumarol) were added to reagents provided according 
to the assay protocol. Rate of change of absorbance (Δ550 nm) was read on a SpectraMax Plus 
384 microplate reader (Molecular Devices, Sunnyvale, CA). Three experimental replicates were 
performed for all cell lines. 
 
Dose-dependent in vitro IB-DNQ cytotoxicity assay 
Cells were seeded at 5000 cells per well in 96 well plates and allowed to attach. Media 
containing varying concentrations (0.003-100μM) of β-lapachone or IB-DNQ was made and 
cells were exposed for 2–h. Treatment media was removed and replaced with drug-free media 
and cells were allowed to grow for 48 h. To investigate the inhibitory effects of dicoumarol on 
NQO1 activity, cells were treated with vehicle (DMSO) or with a combination of 25 μM 
dicoumarol with β-lapachone or IB-DNQ for 2-h. Viability was assessed using the 
sulforhodamine B (SRB) assay.
38
 Percent death was plotted against concentration and fitted to a 
logistic dose response curve. 
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Repeated exposure in vitro IB-DNQ cytotoxicity assay 
The SCCF1 cell line was plated at a density ranging from 8 x 10
4
 to 10
5
 cells in 12 well 
plates (day 0), and incubated overnight. After 24-h (day 1), media was removed from non-
control wells and 1 mL of fresh media with varying concentrations of IB-DNQ (0.1, 0.4, or 3.0 
μM) was placed into respective wells and incubated for 1 h. Wells were then rinsed and replaced 
with 2 mL fresh media and incubated overnight. On days 2-5, serial repeats of day 1 procedures 
were performed until treatment wells had received a total of 5 treatments. After each sequential 
exposure to IB-DNQ, cell death was assessed by SRB daily for up to 5 days. 
The SCCF3 cell line was plated at a density of 8 x 10
4
 cells in 12 well plates (day 0), and 
incubated overnight. After 24-h (day 1), media was removed from non-control wells and 1 mL of 
fresh media with varying concentrations of IB-DNQ (0.1, 0.4, or 3.0 μM) was placed into 
respective wells and incubated for 1 h. Wells were then rinsed and replaced with 2 mL fresh 
media and incubated overnight. On days 2-4, serial repeats of day 1 procedures were performed 
until treatment wells had received a total of 4 treatments. After each sequential exposure to IB-
DNQ, cell death was assessed by SRB daily for up to 4 days. 
The SCCF1 cell line was plated at a density of 5 x 10
4
 cells in 12 well plates (day 0), and 
incubated overnight. After 24-h (day 1), media was removed from non-control wells and 1 mL of 
fresh media with 3.0 μM concentration of IB-DNQ was placed into respective wells and 
incubated for 15 min. Wells were then rinsed and replaced with 2 mL fresh media and incubated 
overnight. On days 2-4, serial repeats of day 1 procedures were performed until treatment wells 
had received a total of 4 treatments. After each sequential exposure to IB-DNQ, cell death was 
assessed by SRB daily for up to 4 days. 
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Animal dosing and sample collection 
Four, healthy, intact, female domestic shorthair cats weighing 4-5 kg were used for all 
pharmacokinetic and toxicologic studies. IB-DNQ was dissolved into HPβCD and sterile water 
was administered intravenously (IV; 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg) and by oral gavage 
(PO; 1.0 mg/kg). Cats received a minimum of four doses of IB-DNQ (3 IV, 1 PO) with a 
minimum washout period of 2 weeks between dosing. Sample collection times for all methods of 
administration were 0, 10, 20, 30, 40, 60, 120, 240, 480 min and 24 h post administration. Cats 
were monitored peri- and post-IB-DNQ administration to document clinical symptoms. Upon 
completion of IB-DNQ administrations, the cats were monitored for an additional 9 months for 
assessment of delayed toxicity. All experiments with healthy research cats were approved by the 
University of Illinois Animal Care and Use Committee. 
 
Plasma IB-DNQ quantification method 
Plasma samples were analyzed with the 5500 QTRAP LC/MS/MS system (Sciex, 
Framingham, MA) in Metabolomics Lab of Roy J. Carver Biotechnology Center, University of 
Illinois at Urbana-Champaign. Software Analyst 1.6.2 was used for data acquisition and analysis. 
The 1200 series HPLC system (Agilent Technologies, Santa Clara, CA) includes a degasser, an 
autosampler, and a binary pump. Multiple reaction monitoring (MRM) was used for 
quantification of IB-DNQ with DNQ as the internal standard. The detection limit of IB-DNQ 
was 1.0 ng/mL) 
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Pharmacokinetic profile of IB-DNQ 
Pharmacokinetic analyses were performed using a non-linear regression program 
(Winnonlin, version 5.1) (Pharsight Corporation, Cary, NC). The area under the curve (AUC), 
terminal half-life (t1/2 β), volume of distribution at steady state (Vdss), total clearance (Cl), 
maximum drug concentration (Cmax) and time at which Cmax was achieved (Tmax) were 
determined. 
 
Hematologic and non-hematologic toxicity assessment 
Assessment of hematologic and non-hematologic tolerability in cats following IB-DNQ 
administration were performed on days 1, 3, 7 and 14 post IB-DNQ administration. Complete 
blood counts (CBC) and serum biochemical analysis were performed by the Veterinary 
Diagnostic Laboratory, University of Illinois at Urbana-Champaign. 
 
Off-target oxidative injury assessment with 8-hydroxydeoxyguanosine ELISA 
Baseline (time 0) and 24-h post IB-DNQ serum samples were evaluated for changes in 8-
hydroxydeoxyguanosine (8-OHdG) concentrations in all cats following the IV IB-DNQ 
administration at the lowest (0.5 mg/kg) and highest dosages (2.0 mg/kg). Concentrations of 8-
OHdG were quantified with the commercially available ELISA kit (Abcam, Cambridge, MA, 
ab201734). 
 
IR-induction of NQO1 expression. 
SCCF3 cells were seeded at 500,000 cells per well in 6 well plates in 2 mL of media and 
incubated overnight at 37°C, 5% CO2.  Cells were irradiated at University of Illinois College of 
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Veterinary Medicine at doses of 2, 4, 6, or 8 Gy.  Cell plates were incubated at 37°C, 5% CO2 for 
varying amounts of time before harvesting at 1, 2, 4, 8, or 24 h post-radiation. Media was 
removed from wells and cells were washed once in 1 mL PBS, which was replaced by 0.5 mL 
trypsin. Cells were incubated for 2-3 min and then 1 mL RPMI 1640 media was added to quench 
trypsin. Cells were scrapped if not already detached and transferred to falconer tubes. Cells were 
centrifuged at 500 x g for 3 min. Media was aspirated off and pellet was resuspended in PBS 
before centrifuging at 500 x g for 3 min. This was repeated twice. Cells were kept at -80°C until 
Western Blot analysis or NQO1 activity assay. 
 
Single agent IB-DNQ treatment in FOSCC patients 
Three patient cats with histologically-confirmed OSCC were recruited for a small pilot 
trial evaluating the tolerability and anticancer activities of IB-DNQ administered IV at a dosage 
of 1.0 mg/kg for 3-4 consecutive treatments over a 4-6 week period. Prior to IB-DNQ treatment, 
baseline complete blood counts and serum chemistry panels were performed, with diagnostic 
assessments repeated immediately prior to each successive IB-DNQ treatment. To quantify 
anticancer activities, computed tomography was performed in all cats prior to IB-DNQ treatment 
to objectively quantify treatment naïve tumor burden, and repeated computed tomography was 
performed 7-days following the last administered dosage of IB-DNQ. Immunohistochemical 
staining for NQO1 was performed on OSCC tissue samples collected from pet cats, and relative 
NQO1 staining intensity graded in comparison to A549. All experiments with pet cats diagnosed 
with OSCC were approved by the University of Illinois Animal Care and Use Committee.   
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Combination treatment IR and IB-DNQ in FOSCC patients 
Two patient cats with histologically-confirmed FOSCC were recruited for a small pilot 
trial evaluating tolerability and anticancer activity of IR irradiation at a dosage of 8 Gy followed 
by systemic administration of IB-DNQ IV at a dosage of 1 mg/kg 4 hours post-radiation for 4 
consecutive treatments over a 4 week period.  Prior to radiation, baseline complete blood counts 
and serum chemistry panels were performed, with diagnostic assessments repeated immediately 
prior to each successive treatment. To quantify anticancer activities, computed tomography was 
performed in all cats prior to treatment to objectively quantify treatment naïve tumor burden, and 
repeated computed tomography was performed 7-days following the last administered dosage of 
IB-DNQ. IHC staining for NQO1 was performed on OSCC tissue samples collected from pet 
cats, and relative NQO1 staining intensity graded in comparison to A549 cells. All experiments 
with pet cats diagnosed with OSCC were approved by the University of Illinois Animal Care and 
Use Committee. 
 
Statistical analyses 
All in vitro experiments were repeated at least three times and results were expressed as mean ± 
SD. Data was compared with lone-way ANOVA and differences of treatment groups relative to 
untreated controls were assessed with post-hoc Dunnet’s test. A p-value <0.05 was considered 
statistically significant; *p < 0.05, **p < 0.01, ***p < 0.001. 
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Chapter 3. Enhancing the therapeutic window of IB-DNQ 
 
3.1. The prodrug approach 
 Prodrugs are a common strategy in drug development as approximately 10% of all drug 
products are prodrugs.
1
 As of 2009 15% of the top selling pharmaceutical products were 
prodrugs
2
 further highlighting the usefulness and commercial appeal to these compounds. The 
concept of prodrugs is rather straight forward: First, a drug molecule is unable to access its target 
or exert its cytotoxic effect due to a obstacle present either inherently to the molecule itself or as 
a result of biology. These obstacles are anything that prevents or limits the usefulness of a drug 
molecule and often are classified into four broad categories:
3-7
 (1) Pharmaceutical: insufficient 
chemical stability, poor aqueous solubility, offensive taste/odor, irritation or pain; (2) 
Pharmacokinetic: poor bioavailability, unfavorable distribution, short duration of action, or 
marked presystemic metabolism; (3) Pharmacodynamic: inadequate site specificity or toxicity; 
and (4) Economical: patent life expiration. In order to overcome or circumvent these obstacles, 
the drug is appended with certain functionalities, called the promoiety. The promoiety allows 
successful crossing of the obstacle and is then cleaved through either enzymatic and/or chemical 
biotransformations releasing the active drug molecule. The drug molecule now at its particular 
target and free of any inactivating modification can exert its cytotoxic action. This prodrug 
strategy is summarized in Fig 3.1. 
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Figure 3.1. Schematic of the concept of prodrugs. 
 
 DNQ possesses the inherent pharmaceutical obstacle of poor aqueous solubility, 
something that was overcome, in part, with second generation derivatives including IB-DNQ. 
These derivatives possess additional steric bulk at the N-methyl position which likely disrupts 
intramolecular π-π stacking interactions resulting in enhanced aqueous solubility.8-10 While this 
improved solubility is satisfactory for in vitro cell and small animal in vivo experiments, in 
thinking about future translation into larger animals and perhaps humans, this solubility could 
become a significant obstacle. Also the pharmacodynamic obstacle of toxicity is a concern going 
further. In felines the dose administered is the same as the MTD making for a very narrow 
therapeutic window and a prodrug that masks the toxicity of the molecule could effectively open 
this window more widely. 
 Addressing the obstacle of aqueous solubility, the most common strategy is through the 
addition of a phosphate group to the drug molecule.
11-15
 These prodrugs typically have good 
stability in the promoiety phosphate to the drug molecule, only undergoing bioconversion 
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through the action of alkaline phosphatases. This selective bioconversion allows for predictable 
behavior of the prodrug.
14-17
 The appending of a phosphate group on the scaffold of IB-DNQ 
should be a good strategy for improving the aqueous solubility of the molecule to increase dose 
as well as help in formulation. 
 The pharmacokinetic obstacle of toxicity is more challenging as the mediators of the off 
target effects are still not clear. Due to the mechanism of action of DNQ and IB-DNQ and the 
low expression of NQO1 outside of the tumor, the prevailing hypothesis is that the adverse 
effects are mediated through the action of one-electron and other two-electron reductases.
18
 
Therefore a prodrug strategy in which the quinone portion of the molecule (the portion 
responsible for reduction and ROS generation) is masked by a promoiety should aid in reducing 
any non-NQO1-mediated ROS generation. Nearly half of all prodrugs make use of an ester 
promoiety
6,17
 and this strategy has been used previously in conjunction with the NQO1 substrate 
β-lapachone.21-23 In this case the active ortho-quinone when masked with an ester functionality, 
led to a 3.5-fold increase in MTD.
21
 Given the similarities between the mechanism of β-
lapachone and IB-DNQ, masking the para-quinone through similar functionality would be 
expected to provide similar results.  
 
3.1.1. Phosphate prodrug 
 Based on the structure and available functional groups of IB-DNQ, it was determined that 
there were three potential sites amenable to addition of a phosphate promoiety. First, a phosphate 
could theoretically be introduced on the secondary nitrogen of the δ-lactam ring through a 
oxymethylene spacer (Fig 3.2). This strategy has been used elsewhere
24-28
 and after cleavage of 
the phosphate through the action of alkaline phosphatases, formaldehyde would be 
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spontaneously released to provide the active drug molecule (Fig. 3.2). The second site is that of 
either amide carbonyl, which likely could be reduced and then conjugated with a phosphate 
moiety. The last site deemed amenable to addition of a phosphate functionality was that of the 
para-quinone. Reduction of the quinone to the hydroquinone and subsequent conjugation with 
phosphorylating agents, in theory would produce a prodrug that not only possessed greater 
aqueous solubility due to addition of a phosphate, but would also mask the active component of 
the molecule to prevent processing by off target enzymes. This potential dual benefit prioritized 
this site for phosphate prodrug synthesis. 
 
Figure 3.2. Rationale of N-oxymethylene phosphate prodrug of IB-DNQ.  
 In order to synthesize the phosphate masked quinone, it was thought that this could be 
accomplished via a reduction of the quinone to the hydroquinone and upon reduction the 
hydroquinone could be phosphorylated with a protected phosphate molecule and upon 
deprotection the desired prodrug would be obtained (Scheme 3.1). Due to the instability of the 
hydroquinone in the presence of oxygen, isolation of the hydroquinone did not seem trivial and 
necessitated that the reduction and phosphorylation be done in one pot. This strategy was applied 
to compound 3-1, a DNQ derivative in which the β-methyl group of the tertiary δ-lactam ring has 
been substituted for an ethyl group. Immediate addition of sodium borohydride to 3-1 resulted in 
the solvent changing from red to deep purple and within 15 min starting material had nearly been 
completely converted as judged from LCMS. Attempting to trap the hydroquinone with either 
POCl3 or diethyl chlorophosphate was unsuccessful and starting material was recovered. Even in 
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the presence of a large excess of phosphate (100 equivalents) no observable product was seen. It 
appears that the para-quinone of IB-DNQ can undergo reduction to the hydroquinone, but that 
introduction of the smallest amount of oxygen, possibly through co-addition with the 
phosphorylating agent, allows the re-oxidation to the quinones species and this reoxidation 
reaction is much more rapid that the phosphorylation reaction. 
 
Scheme 3.1. Synthesis of masked quinone phosphate prodrugs. (a)  Envisioned steps in 
synthesizing phosphate prodrug (b) failed attempts in attempting to produce the envisioned 
phosphate prodrug.  
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3.1.2. Developing a suitable model system 
 
3.1.2.1. Synthesis of quinolonedione model system 
 From the initial investigations on phosphate prodrugs it appeared that it would not be as 
straight forward to synthesize these compounds as previously anticipated therefore, a model 
system was desired to test initial reaction conditions to not waste the more valuable derivatives.  
The 5,8-quinolonedione scaffold presented itself as a useful surrogate for attempting to 
understand the chemistry of IB-DNQ as it possesses similar functionality in the para-quinone and 
adjacent lactam ring (Fig 3.3). In fact this system is as if IB-DNQ was separated into two halves, 
and provides a unique opportunity to understand the reactivity of the two halves of the molecule 
independently. 
 
Figure 3.3. Model systems for IB-DNQ prodrugs. (a) highlighted in red and blue are the 
proposed breakdowns of the IB-DNQ scaffold that are of interest to study in this model system 
(b) the compound composed of the para-quinone and the unsubstituted N-methyl ring will be 
referred to as Hemi-DNQ while (c) Hemi-IB-DNQ refers to the compound comprised of the 
para-quinone and the N-isobutyl ring. 
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A previously reported synthesis of derivatives of this system provided a useful guideline 
for synthesizing these compounds
29,30
 (Scheme 3.2). 2,5-dimethoxyaniline (compound 3-3) was 
dissolved in xylenes and treated with 2,2,6-trimethyl-4H-1,3-dioxin-4-one with heat to yield 2,5-
dimethoxyacetoacetanilide (compound 3-4) in 84% yield.  Knorr cyclization of compound 3-4 
provided the quinolone compound 3-5 in 80% yield. Finally oxidation of 3-5 with ceric 
ammonium nitrate (CAN) produced the desired quinolonedione, Hemi-DNQ, in 87% crude 
yield. 
Scheme 3.2. Synthetic route to Hemi-DNQ. 
 
From Hemi-DNQ, it was envisioned that a late stage alkylation of the δ-lactam nitrogen 
would be able to yield Hemi-IB-DNQ, the complementary half of the IB-DNQ molecule 
(Scheme 3.3). Hemi-DNQ was treated with sodium hydride under inert atmosphere for 15 min 
before the addition of 1-iodo-2-methylpropane. Upon workup; no desired product could be 
isolated, only starting material was isolatable.   
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Scheme 3.3. Late stage functionalization for synthesis of Hemi-IB-DNQ.  
  
The late stage functionalization on Hemi-DNQ seemed problematic as potential 
contamination could be preventing the reaction. Attempts to purify Hemi-DNQ through column 
chromatography led to the discovery that the molecule was unstable to silica and 
decompensation was observed. Rather than using the crude reaction mixture, it was thought that 
alkylation on the Knorr cyclized product, 3-5 might be more fruitful.  The reaction conditions 
used in the attempted conversion of Hemi-DNQ to Hemi-IB-DNQ were then applied to 3-5. The 
reaction was extended overnight and heated at 80°C and the desired product 3-6 was produced in 
5% yield along with the 3% of side product 3-7. The Knorr cyclization product was also 
subjected to sodium iodide, potassium carbonate and 1-Bromo-2-methylpropane overnight at 
elevated temperatures; however only starting material was recovered. 
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'  
Scheme 3.4. Synthesis of Hemi-IB-DNQ through late stage alkylation of compound 3-5.  
 
Due to the low yields and formation of side product in approximately equal yields in the 
alkylation of compound 3-5, alkylation of compound 3-4 was pursued. The desired alkylation 
product 3-8  was not produced when 3-4 was stirred in the presence of sodium iodide, potassium 
carbonate and 1-iodo-2-methylpropane for 48h. Instead alkylation at the α-carbon was observed. 
The increased acidity of this αproton makes it optimal for deprotonation by potassium carbonate 
which can then undergo substitution reaction with the alkyl halide biasing the reaction for 3-9 
not 3-8. 
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Scheme 3.5. Synthesis of tertiary amide 3-8.  
 
 
Late stage alkylation of the quinolonedione scaffold route proved uncooperative; 
therefore a strategy incorporating the alkylation from the onset was implemented (Scheme 3.6). 
The alkylating conditions of sodium iodide, potassium carbonate and 1-iodo-2-methyplpropane 
used in previous attempts of late stage functionalization of the δ-lactam nitrogen were applied to 
2,5-dimethoxyaniline (3-3). The reaction yielded the desired compound 3-10 in 43% yield along 
with small amounts of the di-alkylated compound 3-11 (8%) and starting material. Substitution 
of 1-iodo-2-methylpropane for 1-bromo-2-methylpropane yielded compound 3-10 in 50% yield 
without observable quantities of the di-alkylation product 3-11.  
The synthetic scheme then proceeded as detailed for Hemi-DNQ (Scheme 3.7). 
Treatment of 3-10 with 2,2,6-trimethyl-4H-1,3-dioxin-4-one provided compound 3-8 in 97% 
yield. Knorr cyclization proceeded in 69% yield to yield compound 3-6 and CAN-mediated 
oxidation to Hemi-IB-DNQ proceeded in 47% yield and interestingly this compound was stable 
to column conditions. 
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Scheme 3.6. Synthetic route to alkyl substitution on aniline.  
 
 
 
Scheme 3.7. Synthetic route to Hemi-IB-DNQ. 
 
3.1.2.2. In vitro cytotoxicity of model compounds 
 With both model compounds in hand, it was of interest to see how well these compounds 
mimicked the potency of the parent compound. Hemi-DNQ and Hemi-IB-DNQ were evaluated 
head to head against IB-DNQ for cytotoxicity in A549 cells (Fig 3.4). The cytotoxicity of IB-
DNQ (0.17 ± 0.05 μM) was significantly greater than either of the two model compounds (14.6 ± 
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5.0 μM and 7.5 ± 1.0 μM for Hemi-DNQ and Hemi-IB-DNQ, respectively). Interestingly when 
coincubated with the NQO1 inhibitor dicoumarol, whereas dicoumarol provided protection from 
IB-DNQ-mediated cytotoxicity (2.9 ± 0.5 μM; 17-fold change), both compounds were equally 
cytotoxic in the presence of dicoumarol (9.6 ± 0.7 μM and 6.9 ± 1.7 μM for Hemi-DNQ and 
Hemi-IB-DNQ). This suggest that these compounds are not substrates by NQO1 and likely exert 
their cytotoxicity through another mechanism. 
 
Figure 3.4. Dose-dependent cytotoxic effects of (a) IB-DNQ and model compounds (b) Hemi-
DNQ and (c) Hemi-IB-DNQ in A549 cell lines, in the presence or absence of dicoumarol (25 
uM). Increased susceptibility of A549 cell lines to Hemi-DNQ and Hemi-IB-DNQ in the 
presence of dicoumarol suggests these compounds are detoxified through the action of NQO1. 
 
3.1.2.3. Esterification of model compound quinone 
Next, the model quinolonedione compounds were subjected to reductive esterification 
reactions (Scheme 3.8), utilized in the synthesis of ester prodrug forms of β-lapachone.22 The 
reaction with Hemi-IB-DNQ provided compound 3-12 in 74% yield. The reaction with Hemi-
DNQ, however, did not provide the expected di-esterified product 3-13, but instead a tri-
esterified product, 3-14 in low yield ~5%. The possibilities for the third ester site were either the 
oxygen of the amide carbonyl or the nitrogen of the carbonyl, but with a carbon chemical shift of 
156.52 ppm, this is consistent with the esterification to the oxygen atom of the carbonyl not the 
nitrogen atom in the amide. 
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Scheme 3.8. Synthesis of esterified model compounds. 
 
3.1.3. Ester prodrug  
 It is hypothesized that if the quinone in IB-DNQ could be masked through a promoiety, 
that the tolerability of IB-DNQ could be enhanced. In a compound with a similar mechanism of 
action, 2-electron reduction by NQO1 to induce redox cycling, an ester masking of the ortho-
quinone of β-lapachone was able to increase the MTD by 3.5-fold.21 Since the esters mask the 
portion of the molecule responsible for cytotoxic action, it is presumed that this prodrug form of 
β-lapachone would be processed less by more promiscuous reductases and is the reason for the 
improved MTD. This would suggest that if applied to IB-DNQ, similar improvements in MTD 
should be observed. 
 Previously phosphorylation of the quinone to create a masked quinone prodrug form of 
IB-DNQ was attempted and proved unsuccessful, likely because the phosphorylation reaction 
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was slower than reoxidation to the quinone. Given its success with β-lapachone, however, we 
were optimistic that the esterification reaction may occur more quickly and could be used to 
mask the quinone (Scheme 3.9). 
 
Scheme 3.9. Envisioned route to quinone-masked  ester prodrug of IB-DNQ. 
 
  The esterification conditions used in the model compounds series were then applied to 
IB-DNQ. The reduction of the quinone was mediated by zinc dust and the acetic anhydride was 
provided in large excess in order to attempt to trap the hydroquinone as a di-ester. After 2 h the 
reaction had appeared complete, however upon workup and column chromatography the tri-
esterified product 3-15 (predicted from studies of the model system esterification reactions) was 
not isolated. Likely the ester trapping of the hydroquinone was labile enough that the product 
was not observed. Trapping with propionic anhydride, was attempted under the assumption that 
the longer chain of the ester would render it more stable, but these conditions also did not 
provide the desired trimester prodrug 3-16.  
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Scheme 3.10. Attempted synthesis of quinone-masked ester prodrug of IB-DNQ. 
 
Compound 3-17 was able to be isolated as the hydroquinone following deprotection of 3-
5 with concentrated HBr, and likely the success of esterification of the quinone in these model 
compounds is due to the enhanced stability of their hydroquinones whereas the intact IB-DNQ 
scaffold does not allow for sufficient time as the hydroquinone to undergo efficient esterification 
of the quinone. Cell culture experiments between IB-DNQ and model compounds seem to 
support this less stable hydroquinone hypothesis, as NQO1 could detoxify Hemi-DNQ and 
Hemi-IB-DNQ and not IB-DNQ, which would only result if the hydroquinone form of the 
model compounds were stable enough to undergo conjugation. 
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Scheme 3.11. Isolation of hydroquinone form of Hemi-DNQ. 
 
3.2. DNQ derivatives 
 
3.2.1. Novel DNQ derivatives 
 
3.2.1.1. SAR of DNQ 
 Previously work had been done to establish a correlation between NQO1 processing and 
cell culture toxicity using a panel of 25 DNQ derivatives and constitutes the entire known 
structure activity relationship of DNQ.
8
 Primarily consisting of alkyl substitutions, modifications 
were made solely to the methyl position on the secondary δ-lactam ring (blue circle), the methyl 
position on the tertiary δ-lactam ring (green circle), the N-methyl position (red circle) or the 
unsubstituted nitrogen (yellow circle) or to a combination of 2, 3 or all of these sites (Fig, 3.5). 
Multiple substitutions at these four sites resulted in less efficient processing of the derivatives as 
compared to DNQ (up to 30-fold). Small substitutions at either δ-lactam ring, such as a methyl to 
ethyl substitution, were tolerated, however the potency of these compounds were 10-fold lower. 
Longer chain, more sterically encumbering substitutions at these positions reduced the 
processing efficiency as well as potency of the derivatives. Substitution at the N-methyl position 
(red circle Fig 3.5) with longer and more bulky alkyl chains was largely tolerated without 
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significant reduction in either NQO1 processing or cellular potency.
8
 These derivatives also 
tended to have improved MTDs in mice compared to DNQ.
10
 However, as it stands currently, the 
SAR of DNQ has been limited to these few specific site manipulations that have been entirely 
composed of alkyl substitutions. Investigation into the SAR of other positions around the DNQ 
scaffold, as well as studying of the electronic effects of substituents on the processing and 
cytotoxicity of DNQ could provide new, interesting derivatives that may possess more favorable 
in vivo pharmacokinetics and tolerability. 
 
Figure 3.5. Structure activity relationship of DNQ scaffold. 
 
3.2.1.2. Modeling evidence 
 The most obvious site for further investigation into the SAR of DNQ is that of the α-
carbon of the δ-lactam ring. Computational modeling of molecules generated in silico with alkyl 
substitutions at this position suggested that modification at this position should minimally 
perturb NQO1 processing while perturbing to a greater extent processing by NADPH 
cytochrome P450 reductase (P450R), a one-electron reductase thought to be responsible for 
possible off target effects of DNQ (Fig. 3.6).
18
 From the modeling data α-carbon substitutions 
should lead to steric clashing of the derivative with the active site cofactors, which, upon 
resolving and adopting a minimal energy conformation, would place the quinone portion outside 
of the active site and lead to less efficient electron transfer (compounds 3-18, 3-19). Therefore it 
was hypothesized that these derivatives would have more selectivity for 2-electron reduction by 
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NQO1 over one-electron reduction by other reductases and that this selectivity would translate 
into more tolerability in vivo. 
 
Figure 3.6. Computational modeling of DNQ, IB-DNQ and two novel molecules suggests that 
modification of the α-carbon should not perturb NQO1 processing (a-d) while influencing to a 
greater extent one electron processing as modeled by P450R (e-h). 
 
3.2.1.3. Synthesis 
 From the current synthesis of IB-DNQ it appeared challenging to synthesize an 
iodoamide cross coupling partner with substitution at the desired position, so a late stage 
functionalization strategy was adopted instead. It was hypothesized that if IB-DNQ could be 
halogenated at the position then this could facilitate a Suzuki-cross coupling reaction that would 
be able to be adaptable to a diverse set of cross coupling partners to create a vast set of 
derivatives. Addition of NBS to IB-DNQ overnight was able to produce a single brominated 
product 3-20 OR 3-21 in 95% yield. Since the location of the bromine and identity of which 
compound the product is has not been determined this compound will be referred to as Br-IB-
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DNQ. Similarly the reaction with NIS afforded a single product I-IB-DNQ (either 3-22 or 3-23), 
although mild heating was necessary, in 44% yield. The reaction with NCS yielded three 
products, two singly chlorinated (3-24 and 3-25) in 14% (Cla-IB-DNQ) and 24% (Clb-IB-DNQ) 
yield and one doubly chlorinated compound, 3-26 or Cl2-IB-DNQ (41%), that were separable by 
column chromatography. The iodinated and brominated IB-DNQ derivatives could serve as 
potential platforms for subsequent Suzuki coupling reactions. 
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Scheme 3.12. Synthesis of halogenated IB-DNQ derivatives. 
 
3.2.1.4. Cytotoxicity of Halo-IB-DNQ derivatives 
 The five halogenated IB-DNQ derivatives (I-IB-DNQ, Br-IB-DNQ, Cla-IBDNQ, Clb-
IBDNQ, Cl2-IBDNQ) were selected to evaluate their abilities to induce cancer cell death in an 
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NQO1 expressing non-small cell lung carcinoma cell line (A549). Cells were exposed to a range 
of concentrations in both the presence and absence of NQO1 inhibitor ES936. Compared to the 
cytotoxicity of IB-DNQ (0.17 ± 0.05 μM) all five derivatives saw at least 40-fold decrease in 
potency (Table 3.1). Among the chlorinated derivative series there was an observable difference 
between the two mono-chlorinated compounds (7.9 ± 1.4 μM Clb-IB-DNQ vs. 13 ± 1 μM Cla-
IB-DNQ) and an additional chlorine atom resulted in a drastic decrease in potency over both of 
the mono-chlorinated compounds. ES936 provided protection from cytotoxicity in all cases, 
indicating that these are still substrates for NQO1, able to be processed and undergo redox 
cycling. It may be that the electron-withdrawing nature of the halogen substituents is able to 
inductively pull electron density from the quinone core and as a result make it more difficult for 
NQO1 to mediate the two electron reduction to the hydroquinone. Alternatively the electron 
withdrawing nature may help to stabilize the molecule as the hydroquinone and the prolonged 
existence of the hydroquinone form would enable more conjugation and excretion from the cell 
leading to less efficient cytotoxic redox cycling. However, in this second case it might be 
expected that in the presence of NQO1 inhibitor these compounds would become more 
cytotoxic, which is in opposition to what is seen in cell culture. Therefore it is more likely that 
these compounds are less potent due to the more difficult reduction of the quinone and 
derivatives possessing either an alkyl or electron donating substituent in this position would be 
interesting candidate compounds to test this hypothesis.  
An alternative explanation for the decrease in potency in the Halo-IB-DNQ derivatives 
could be that the molecule does not sterically tolerate any derivatization at this position. A 
decrease in potency does correlate with the atomic radius of the halogen, with the chlorinated 
derivative being most potent and having smallest atomic radius and the iodinated derivative 
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being least potent and having the largest atomic radius, with the brominated derivative 
somewhere in between. However, from the computational modeling experiment performed in 
Section 3.2.1.2 derivatization at this position should be tolerated and it is more likely that this 
decrease in potency relates to the electronic effects rather than any steric effects. 
 
Table 3.1. Potency of Halo-IB-DNQ derivatives in A549 cells 
Compound IC50 (μM) 
IC50 +ES936/DIC 
(μM) 
Fold 
protection 
IB-DNQ 0.17 ± 0.05 2.9 ± 0.5 17 
Cla-IB-DNQ 13 ± 1 48 ± 8 4 
Clb-IB-DNQ 7.9 ± 1.4 59 ± 15  7 
Cl2-IB-DNQ 59 ± 9 > 100 > 1.7 
Br-IB-DNQ 9.3 ± 0.3 48 ± 5 5 
I-IBDNQ0 21 ± 4 65 ± 13 3 
 
3.2.2. Revisiting previously synthesized derivatives 
 In previous work,
8
 derivatives of DNQ had been synthesized according to a modular 
route to establish a correlation between NQO1 processing activity and in vitro cytotoxicity. A 
diverse set of 25 DNQ derivatives was created which lead to the discovery of IB-DNQ. Due to 
the increased solubility over DNQ and better in vivo tolerability in mouse models (14 mg/kg vs 9 
mg/kg), IB-DNQ proceeded as the molecule of choice. The progression into animal models 
larger than mice necessitated large amounts of compound and the relatively cheap price of 
isobutylamine made it more attractive than other derivatives. After observing the effectiveness in 
of IB-DNQ in feline OSCC patients, we wanted to take a step back and evaluate if IB-DNQ 
would in fact be the best compound to proceed forward with or if maybe there was a previously 
synthesized derivative that would have greater therapeutic potential.  
In revisiting this set of 25 derivatives,
10
 four derivatives were identified with improved 
MTD over IB-DNQ in mouse models: propyl-DNQ or P-DNQ (17 mg/kg), Isopentyl-DNQ or 
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IP-DNQ (15 mg/kg), neopentyl-DNQ (21 mg/kg) or NP-DNQ and 3,3-dimethylbutyl-DNQ (22 
mg/kg) or 3,3-DMB-DNQ. Furthermore, these derivatives possessed similar catalytic 
efficiencies and maintained similar potencies in breast cancer and lung cancer cell lines to IB-
DNQ. (Fig. 3.7) Therefore these compounds were selected for synthesis and evaluation for 
potential improvements in pharmacokinetics and MTD over IB-DNQ, to help inform decision of 
which derivative to move forward with into the clinic. 
 
Figure 3.7. Properties of previously synthesized DNQ derivatives. (a) IB-DNQ (b) derivatives to 
be evaluated and compared to IB-DNQ. MTD (green), catalytic efficiency (black), IC50 against 
MCF-7 breast cancer cell line (red), IC50 against A549 cell line (blue) demonstrate the 
similarities and differences between IB-DNQ and potential derivatives. 
 
3.2.2.1. Synthetic scheme 
 The synthesis of previous derivatives could be achieved by the previous synthetic 
route
8,31
 (Schemes 3.13 and 3.14).  From 2,6-dichloroanisole (3-27), deprotonation with lithium 
disopropylamide (LDA) and quenching with trimethylsilyl chloride provided selective silyation 
at the 3- and 5-positions of the anisole (3-28). Iododesilyation was then carried out on 3-28 
through the action of iodine monochloride at 0°C to produce 3-29. Subjection of 3-29 to Miyaura 
borylation conditions provided the cross-coupling partner 3-30 in yields in line with previous 
reports.
31
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The alkyl-iodoamide coupling partner was synthesized via an amide coupling of ethyl 2-
butynoate (3-31) and the desired alkyl amine and through the action of sodium iodide in acetic 
acid was converted to the (Z)-iodoolefin.  
Due to the lability of the para-methoxybenzyl (PMB) group under acidic conditions, the 
PMB-iodoamide coupling partner was synthesized from 2-butynoic acid (3-31) first through the 
action of sodium iodide and acetic acid to produce the (Z)-iodoolefin carboxylic acid, 3-43, and 
then  through the conversion of the carboxylic acid to the PMB-amide, 3-44, in two steps via an 
acyl chloride intermediate. 
  
 
Scheme 3.13. Synthesis of cross coupling partners. (top) center piece, (middle) alkyl 
iodoamides, and (bottom) PMB-amide. 
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Both the alkyl-iodoamide (3-37-41) and PMB-iodoamide, 3-44, were utilized in a mixed 
Suzuki cross coupling reaction with coupling partner 3-30. After purification via flash 
chromatography to isolate the desired product, a Buchwald-Hartwig amidation was performed to 
form the tricyclic ring system. Reflux in concentrated HBr yielded the deprotected  monophenol. 
The monophenol was subjected to salcomine-catalyzed oxidation in the presence of oxygen 
atmosphere to produce desired DNQ derivatives (Scheme 3.14). 
 
Scheme 3.14. General synthesis of DNQ derivatives from cross coupling partners. 
 
Application of this scheme was able to produce IB-DNQ, IP-DNQ and P-DNQ in useful 
amounts for clinical experiments; however NP-DNQ was much more difficult. It became 
apparent that there were two steps in the reaction scheme that could be altered to increase 
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productivity, the first being the amine coupling reaction with ethyl 2-butynoate and the second 
being the final salcomine-mediated oxidation reaction. 
 While the amine coupling produces isopentylamine and isobutylamine derived products 
in 72% and 56% yield, the coupling with neopentylamine is less efficient (34% yield). Due to the 
cost associated with these more sterically encumbered amines and also the lower quantity 
available to utilize in the synthetic scheme, a more efficient was of synthesizing these iodo-
amides was necessary. The steric bulk of the amine likely causes a sluggish reaction, therefore it 
was thought that conversion of the ester to a more reactive carbonyl may facilitate the speed of 
the reaction and lead to improved yields. Such a route is implemented in the synthesis of PMB-
iodoamide, necessary due to the sensitivity of the PMB group to acidic conditions, in which the 
carboxylic acid is converted to an acyl chloride before undergoing reaction with amine. Since 
this route is used due to the PMB group’s sensitivity to the conditions of the iodination reaction, 
we saw no reason why this could not be applied to synthesis of the alkyl iodoamides as well. 
Conversion of 3-42 to the 3-43 through sodium iodide and acetic acid produced the 3-43 
in 95% yield. This compound was then converted to the corresponding acyl chloride through the 
action of oxalyl chloride and then in the same pot, in the presence of triethylamine, the desired 
alkyl amine was added. The yield for the sterically encumbered neopentylamine was nearly 
quantitative (99% yield) and high yields were also obtained for the other alkyl amines: 3,3-
dimethylbutylamine 91%, isobutylamine 94%. Comparison of the two steps yields of the old 
route and this modified route increased 50% to 89% for 3-37 and 27% to 94% for 3-40. 
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Scheme 3.15. Comparison of old and modified routes for synthesizing alkyl-iodo-amides for 
cross coupling reactions. 
 
With no longer limiting amounts of iodoamides, attention was turned to the oxidation 
step of the reaction scheme. Yields for these derivatives ranged anywhere from 15 to 30% and 
these low yields were limiting the production of the larger quantities of alternative DNQ 
derivatives necessary for clinical experiments. Four hypotheses were developed in an attempt to 
explain the low yield in this reaction. The first was that excess salt in the phenol starting material 
may be inflating starting material mass leading to artificially low yields. Therefore the product 
was suspended in DI water, sonicated to remove salts, centrifuged and filtered to yield “purified” 
starting material. However this did not appear to be a significant contributor as the yield of IB-
DNQ only increased from 15% to 23% when using “purified” compound.  
Since the phenol compound is extremely insoluble, the second hypothesis was that not all 
of the starting material is going into solution to allow for the transformation. Testing this 
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hypothesis, the phenol was heated until the solution was clear to create a supersaturated solution 
before being subjected to the normal reaction conditions. Unfortunately no change in the yield of 
the reaction was observed with this modification, eliminating it as a potential contributor to the 
low reaction yields. 
 A third hypothesis was that the oxygen was not sufficiently available to induce oxidation 
of the compound. As the reaction typically is set up so that the flask is kept under an oxygen 
atmosphere by placing a balloon full of O2 over the opening of the flask, the oxygen may only be 
present at the solution-atmosphere interface. To enhance contact with oxygen, O2 was bubbled 
into the solution instead of just presenting an oxygen atmosphere. Implementing this change into 
the reaction protocol increased the yield of the oxidation reaction of IB-DNQ from 15% to 30%. 
 The last hypothesis was that over the time frame of the reaction, the salcomine catalyst 
was undergoing deactivation and that this deactivation was no longer allowing for conversion of 
starting material to product. Deactivation of salcomine had previously been reported in a study 
looking at the oxidation of monophenols to quinones.
32
 To compensate for any deactivation, 
additions of 6 mol% catalyst were added to the solution every three hours for up to three 
additions. The resulting yield of the reaction increased from 15% to 40%. A further bump in 
yield (40 to 49%) was observed when combining the O2 and catalyst modifications. 
 
3.2.2.2. Pharmacokinetics of derivatives 
Pharmacokinetics were derived from 4 healthy research cats, following single-dose, IV 
administration at 2.0 mg/kg of P-DNQ, IP-DNQ and NP-DNQ; average peak plasma 
concentration levels were 6270.5 ± 685.2 ng/mL (20.1 ± 2.2 μM), 2535.1 ± 614.8 ng/mL (7.4 ± 
1.8 μM), and 3992.5 ng/mL ± 1873.9 (11.7 ± 5.5 μM), respectively (Fig 3.8). Terminal 
91 
 
elimination half-life at 2.0 mg/kg IV was 606 ± 90 min, 496.2 ± 141.0 min, and 294 ± 72 min for 
P-DNQ, NP-DNQ and IP-DNQ, respectively. Full pharmacokinetic parameters for DNQ 
derivatives administered IV are detailed in Table 3.2. 
 
Figure 3.8. Pharmacokinetic profile of intravenous DNQ derivatives dosed at 2.0 mg/kg as an 
aqueous solution in HPβCD. Data represented as average ± SD. 
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Table 3.2. Pharmacokinetic parameters of IB-DNQ following 2.0 mg/kg IV administration 
 
IP-DNQ NP-DNQ P-DNQ IB-DNQ 
AUC0-inf (ng x hr/mL) 1539.8 ± 560.4 1871.5 ± 736.3 10025.4 ± 7743.9 1884.4 ± 780.7 
K10-HL (min) 24.6 ± 3.0 21.0 ± 3.6 66 ± 54 13.7 ± 1.5 
α (1/min) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 
β (1/min) 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0  
t1/2 α (min) 23.4 ± 2.4 17.4 ± 1.8 22.2 ± 5.4 10.9 ± 1.5 
t1/2 β (min) 294 ± 72 496.2 ± 141.0 606.0 ±  234.0 115.8 ± 90.7 
A (ng/mL) 2481.3 ± 597.9 3969.3 ± 1867.3 5898.6 ± 807.3 5582.9 ± 2395.2 
B (ng/mL) 53.8 ± 21.4 23.2 ± 7.3 371.9 ± 289.8 198.5 ± 162.5 
Cmax (ng/mL) 2535.1 ± 614.8 3992.5 ± 1873.9 6270.5 ± 685.2 3426.3 ± 1249.7 
Cl (mL/min) 92.5 ± 39.8 79.3 ± 36.9 20.3 ± 10.6 73.9 ± 39.8 
AUMC0-inf (ng x hr x 
hr/mL) 
3423.3 ± 2122.6 3609.9 ± 367.1 143,614.8 ± 
173,487.9 
2138.3 ± 2455.4 
MRT (min) 120.0 ± 34.2 156.0 ± 96.0 552.0 ± 402.0 57.7 ± 51.0 
Vss (mL) 9902.9 ± 1716.6 15,715.5 ± 15,834.4 7030.2 ± 2001.2 3409.0 ± 1857.8 
V2 (mL) 6817.8 ± 813.4 13,133.2 ± 14,203.5 5865.1 ± 2048.3 1956.2 ± 2043.2 
Cld2 (mL/min) 1395.0 ± 582.2 1139.8 ± 1100.5 10006.5 ± 257.4 13.5 ± 5.0 
Parameters derived from 4 research cats and expressed as average ± SD 
 
3.2.2.3. Tolerability of derivatives 
To assess the tolerability of P-DNQ, IP-DNQ and NP-DNQ, we evaluated hematologic, 
non-hematologic, and clinical observational toxicities associated with each administration. Each 
feline subject was monitored for the development of acute clinical side effects peri-infusion and 
post-infusion (30 min). Side effects are comparable to IB-DNQ with the most notable clinical 
symptoms being hyper-salivation, mucous-y defecation, urination and tachypnea. P-DNQ the 
effects are significantly more severe than IB-DNQ with cats becoming very reactive during the 
infusion (increased vocalization and jumping). Hyper-salivation and tachypnea were both more 
severe and persisted longer. Cats seemed lethargic for multiple hours post infusion, whereas with 
IB-DNQ these effects lasted an hour at the longest. IP-DNQ shows similar severity to effects 
seen with IB-DNQ. NP-DNQ had no observable signs of hyper-salivation or tachypnea but more 
labored breathing during and immediately post-administration may indicate some degree of a 
respiratory side effect. 
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3.2.2.4. NQO1-independent ROS generation 
 The ideal compound would produce maximal levels of ROS and cell death in cancers 
expressing NQO1 while producing minimal levels of ROS and cell death in normal tissues that 
do not express NQO1 to any appreciable amount. A compound that was able to do this would 
theoretically have the largest therapeutic window and should be prioritized going forward. The 
four derivatives (IB-DNQ, P-DNQ, IP-DNQ, and NP-DNQ) along with DNQ were evaluated 
for their ability to induce superoxide (ROS) and cell death at various concentrations in the 
NQO1-deficient head and neck cancer cell line, JHU029 (Fig 3.9., Table 3.3, Fig. 3.10, Table 
3.4). At relevant biological concentrations (5-10 μM), NP-DNQ was able to exert the greatest 
cytotoxicity in these NQO1-deficient cells (Fig. 3.9, Table 3.3), in contrast to  what was expected 
based on the previous tolerability studies. Across these same concentrations IP-DNQ showed the 
lowest levels of cytotoxicity while DNQ, IB-DNQ and P-DNQ all showed intermediate levels 
that did not really differentiate from each other. NP-DNQ showed the highest levels of ROS 
(assessed as MitoSox Red staining of mitochondrial superoxide) with IB-DNQ also 
demonstrating high levels of ROS (Figure 3.10, Table 3.4). This seems to suggest that NP-DNQ 
and IB-DNQ may be more susceptible to NQO1-independent redox cycling than IP-DNQ or P-
DNQ 
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Figure 3.9. Cytotoxicity responses of DNQ derivatives in JHU029 cells. Experiment was 
conducted by Dr. Hyang Yeon. 
 
Table 3.3. Cytotoxicity of DNQ derivatives in JHU029 cells 
Concentration  DNQ IB-DNQ P-DNQ IP-DNQ NP-DNQ 
1 μM 0.49 ± 4.85 8.36 ± 2.27 10.63 ± 4.67 1.92 ± 4.62 11.97 ± 3.03 
5 μM 33.05 ± 6.02 36.60 ± 4.26 35.65 ± 8.88 24.57 ± 5.73 48.34 ± 3.62 
10 μM 56.38 ± 1.87 58.83 ± 0.99 57.12 ± 9.67 46.71 ± 8.75 70.61 ± 1.72 
25 μM 79.87 ± 3.27 82.13 ± 0.93 85.20 ± 1.81 79.75 ± 1.71 91.04 ± 0.95 
*Data expressed as Mean ± SD. 
 
 
 
Figure 3.10. Mitochondrial superoxide generation of DNQ derivatives in JHU029 cells. 
Experiment was conducted by Dr. Hyang Yeon. 
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Table 3.4. Fold change in mitochondrial superoxide generation in JHU029 cells 
Concentration  DNQ IB-DNQ P-DNQ IP-DNQ NP-DNQ 
0.5 μM 1.15 1.21  1.18  1.23  1.58  
1 μM 1.44 1.46  1.38  1.39  2.21  
5 μM 2.81 3.98  2.79  3.14  7.14  
10 μM 4.20 6.79  4.07  4.81  11.27  
*Data expressed as Mean 
 
These derivatives were then evaluated in an isogenic cell line pair for their ability to 
cause cell death and generate superoxide. MDA-MB-231 breast cancer cells transfected with 
NQO1 showed extreme sensitivity to all derivatives even at the lowest concentration tested (1 
μM) and no significant differences were observed in cell death between the derivatives (Fig 3.11, 
Table 3.5). All derivatives produced high levels of ROS (at least a 7.5-fold increase in ROS 
levels compared to DMSO treated controls) (Fig. 3.12, Table 3.6), with NP-DNQ demonstrating 
the most robust superoxide formation.  In the isogenic NQO1-deficient MDA-MB-231 cells, the 
cytotoxicity was significantly diminished; however, NP-DNQ was able to exert a much greater 
amount of cell death than any of the other derivatives (Fig 3.11, Table 3.5). Superoxide 
formation was also much higher in cells treated with NP-DNQ, (Fig. 3.12, Table 3.6) and 
mirrored that seen with the JHU029 cell line (Fig. 3.10, Table 3.4). Comparisons in superoxide 
formation between isogenic cell line pair for each derivative can be found in Table 3.7. 
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Figure 3.11. Cytotoxicity responses of DNQ derivatives in MDA-MB-231 cells transfected with 
NQO1 (NQO1+) or empty vector (NQO1-). Experiment was conducted by Dr. Hyang Yeon. 
 
 
Table 3.5. Cell death of DNQ derivatives in isogenic MDA-MB-231 cell lines 
 Concentration DNQ IB-DNQ P-DNQ IP-DNQ NP-DNQ 
N
Q
O
1
- 1 μM 10.84 ± 3.86 10.85 ± 2.22 3.70 ± 3.70 6.17 ± 3.66 9.74 ± 5.56 
5 μM 21.44 ± 3.56 15.34 ± 2.95 12.38 ± 5.29 13.41 ± 1.93 40.24 ± 2.16 
10 μM 32.00 ± 2.85 35.82 ± 4.66 21.25 ± 2.21 20.30 ± 1.68 53.15 ± 2.97 
25 μM 58.45 ± 4.52 59.47 ± 5.36 61.53 ± 5.97 58.76 ± 4.01 84.34 ± 1.73 
N
Q
O
1
+
 1 μM 87.18 ± 1.18 84.20 ± 1.68 85.36 ± 2.58 83.54 ± 2.03 91.11 ± 1.83 
5 μM 95.84 ± 1.46 93.94 ± 1.66 96.49 ± 0.69 93.96 ± 1.00 97.97 ± 0.25 
10 μM 97.78 ± 0.72 97.19 ± 0.85 98.22 ± 0.21 97.10 ± 0.41 99.01 ± 0.08 
25 μM 99.40 ± 0.28 99.01 ± 0.33 99.59 ± 0.17 99.54 ± 0.10 99.72 ± 0.05 
*Data expressed as Mean ± SD. 
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Figure 3.12. Mitochondrial superoxide generation elicited by DNQ derivatives in MDA-MB-231 
isogenic cell line pairs transfected with NQO1 (NQO1+) or empty vector (NQO1-). Experiment 
was conducted by Dr. Hyang Yeon. 
 
Table 3.6. Fold change in mitochondrial superoxide generation of DNQ derivatives in isogenic 
MDA-MB-231 cell line pairs 
 MDA-MB-231 
(NQO1
+
) 
MDA-MB-231 
(NQO1
-
) 
Concentration 1 μM 10 μM 1 μM 10 μM 
DNQ 7.8 7.6 1.7 5.2 
IB-DNQ 9.6 11.2 1.9 7.4 
P-DNQ 8.7 9.1 1.8 4.8 
IP-DNQ 8.7 9.8 1.6 4.9 
NP-DNQ 10.4 14.4 2.8 10.5 
 
Table 3.7. Comparison between mitochondrial superoxide generation in isogenic MDA-MB-231 
cell line pairs for DNQ derivatives 
Compound 
NQO1
+
 ROS: 
NQO1
-
 ROS 
DNQ 4.6 
IB-DNQ 5.1 
P-DNQ 48 
IP-DNQ 5.4 
NP-DNQ 3.7 
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3.3. Summary  
 Recent clinical evaluations of IB-DNQ in felines have provided optimism for the future 
of NQO1-targeted therapies not only in companion animal disease but for the translation into 
humans as well. However, as it currently stands the effective dose of IB-DNQ in felines is the 
same as its maximum tolerated dose which offers a very narrow therapeutic window. Therefore 
developing strategies for widening the therapeutic window of IB-DNQ is essential for its future 
development and we cannot simply hope that humans will respond as favorably to dosing at the 
MTD as our feline counterparts seem to tolerate. 
 Often this window can be extended through creating a prodrug form of the drug molecule 
to mitigate off-target toxicity. While conceptually this appears to be a useful strategy for IB-
DNQ, through masking of the active para-quinone moiety with promoiety functional groups, it is 
not straightforward. The ability of para-quinone of IB-DNQ to undergo reduction to a 
hydroquinone and quickly reoxidize back to the parent quinone is a property of the molecule 
which makes it the most efficient NQO1 redox substrate known to date. Unfortunately this same 
property appears to make it challenging to mask the quinone in a prodrug, as the reoxidation 
appears to occur much faster than any conjugation reaction. While this strategy was able to be 
implemented with fellow NQO1 substrate β-lapachone, β-lapachone also is not processed as 
efficiently by NQO1 as IB-DNQ which may be a result of slower reoxidation kinetics which 
facilitate esterification of the quinone. While a strategy to prodrug IB-DNQ still may remain 
possible, it would appear challenging to accomplish. 
 Alternative derivatives of IB-DNQ may be the key to extending the therapeutic window. 
The SAR of IB-DNQ at the α-carbons of the δ-lactam rings remain largely unexplored. While 
introduction of a halogen at this position seems to abolish potency, the effects of substitution at 
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this position are incomplete. Bromination and iodination at this position prime the compound for 
quick diversification through cross coupling reactions in order to further interrogate the structure 
activity relationship of the molecule, which will hopefully yield exciting compounds in the 
future. Parallel to this quest for new derivatives is the re-evaluation of older derivatives. Through 
improvements in the synthetic yields of alkyl iodoamides and salcomine-mediated oxidation, 
derivatives with more sterically encumbering, expensive amines can now be evaluated to a 
greater extent in animal models, which may lead to the discovery of a better derivative to move 
forward with in the clinic. We can already see differences between the pharmacokinetics and 
tolerability of some of these derivatives; however, at this point no compound has significantly 
better properties than IB-DNQ (Fig. 3.13).  
It appears that IB-DNQ should proceed as the derivative of choice in felids with OSCC, 
as preliminary findings show it is effective and toxicity has not yet been an issue even though 
dosing is conducted at the MTD. Potentially IP-DNQ might be considered for further use. While 
side effects are similar to that of IB-DNQ in appearance, duration and severity, IP-DNQ 
possesses a slightly longer half-life than that of IB-DNQ. Despite having a lower Cmax than IB-
DNQ, this prolonged half-life may allow effective concentrations of IP-DNQ to persist in vivo 
for a longer duration than IB-DNQ while also avoiding any potential off-target effects that could 
result from a high Cmax. Also the greater ratio of NQO1
=
:NQO1
-
 ROS experienced by IP-DNQ in 
isogenic cell lines suggests that the therapeutic window of IP-DNQ could be larger than that of 
IB-DNQ.  
At this point in the development of deoxynyboquinones as anticancer agents for HNSCC, 
either IB-DNQ or IP-DNQ should be considered moving forward. To this point neither 
derivative possesses properties that would be considered superior to the other; however, IP-DNQ 
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does appear to have some improved properties and perhaps these could eventually differentiate 
themselves in other species, similar to what is seen in mice. In felines the MTD window of these 
derivatives may be compressed due to the sensitivity of felids to oxidative damage, and in a 
species, like canines, that are less sensitive to oxidative stress perhaps one of these derivatives 
would begin to show superiority. Other assays such as methemoglobin formation assays and 
tumor penetrance assays could be used to aid in this decision of which derivative to move 
forward with. 
 
Figure 3.13. Head to head comparison chart of DNQ derivatives and performance in assays done 
to date. *observable adverse effects with IB-DNQ persisted for 1h and included: ptyalism, 
tachypnea, urination, emesis, and lethargy. 
 
3.4. Materials and methods 
 General chemical reagents were purchased from Sigma Aldrich. Pd/X-Phos catalyst and 
X-Phos ligand were purchased as a 1:1 admixture from Strem Chemicals, Inc. (Newburyport, 
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MA). Lithium diisopropylamide was purchased as a 2.0 M solution in THF from Acros Organics 
(Morris Plains, NJ). Ethyl 2-butynoate, 1,2-dimethoxyethane and iodine monochloride were 
purchased from GFS Chemicals (Powell, OH). 2-butynoic acid and neopentylamine were 
purchased from Oakwood Chemical (Estill, SC). PdCl2(dppf) catalyst and bis-pinacolboronate 
were purchased from CombiPhos Catalysts (Princeton, NJ). 2,6-dichloroanisole was purchased 
from TCI America (Portland, OR). 4-methoxybenzylamine and oxalyl chloride were purchased 
from Alfa Aesar (Heysham, Lancashire, United Kingdom). All reagents were used without 
further purification unless otherwise noted. Solvents were dried by passage through columns 
packed with activated alumina (THF, CH2Cl2, DMSO). 
 
1
H-NMR and 
13
C-NMR were recorded on Varian Unity spectrometers at 400/500 MHz 
and 125 MHz, respectively. Spectra generated from a solution of CDCl3 were referenced to 
residual chloroform (
1H: δ 7.26 ppm; 13C: δ 77.16 ppm). Spectra generated from a solution of 
CD3OD were referenced to residual methanol (
1H: δ 3.31 ppm). 
 
To an oven-dried flask and stir bar under nitrogen was added 2,6-dichloroanisole (3-27, 
10.8 mL, 78.8 mmol) and dry THF (80 mL). The flask was chilled in a dry ice/isopropanol bath 
and lithium diisopropylamine (100 mL, 2.0M solution) was added dropwise via syringe. The 
reaction was stirred for 4h and kept at temperature -78°C. TMSCl (26 mL, 204.9 mmol) was 
added and mixture was stirred overnight warming to room temperature. A white precipitate had 
formed and reaction was quenched with distilled water (60 mL), which also dissolved the 
precipitate. Mixture was diluted with 1M HCl and separated after addition of ether. Aqueous 
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fraction was extracted once more with ether and then the combined organic fractions were 
washed with brine, dried over MgSO4 and evaporated to a pale yellow oil that solidified under 
vacuum over the course of the following week. Reaction yielded 3-28 (22.23 g, 69.1 mmol) in 
88% yield that was used in further reactions without additional purification. Spectra of 3-28 was 
consistent with that previously report.
31 
 
Iodine monochloride (33.88 g, 209 mmol) was weighed into a round-bottom flask with stir bar 
and dissolved in CH2Cl2. The flask was chilled in an ice-water bath and flask was adapted with 
addition funnel. 3-28 (22.23g, 69.1 mmol) was dissolved in minimal CH2Cl2 (10 mL) and added 
to addition funnel. Stopcock was opened to add 3-28 to flask in a dropwise manner over the span 
of 1h, keeping solution temperature below 20°C. After addition used additional CH2Cl2 to wash 
addition funnel and let stir for 0.5h. Added distilled water to flask and transferred to an 
Erlenmeyer with aid of CH2Cl2. Added sodium sulfite until color dissipated and separated. 
Extracted aqueous fraction with CH2Cl2 three times and washed combined organic fraction with 
brine before drying over MgSO4. Filtered and rotovapped to yield a hairy white-brown solid, 3-
29 (27.75 g, 64.73 mmol, 94% yield). Spectra of 3-29 was consistent with that previously 
report.
31
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To a hot oven-dried flask with stir bar was added KOAc (35.98 g, 366.6 mmol) and vacuum was 
applied to dry the salt until flask was cool. To this flask was added 3-29 (26.19 g, 61.1 mmol), 
PdCl2(dppf) (7.48 g, 9.16 mmol, 15 mol%), and B2pin2 (34.15 g, 134.5 mmol). Flask was 
evacuated and backfilled with nitrogen three times. Dry DMSO was added via syringe and 
mixture was placed in an oil bath at 90°C. Mixture was allowed to stir for 23h and then after 
cooling was poured into a separatory funnel with additional DMSO. Mixture was extracted with 
hexanes and combined hexane fractions were washed with water until the organic layer was 
clear. Organic fraction was then dried over MgSO4 and evaporated to an off-white solid. The 
reaction yielded 3-30 (18.31 g, 31.0 mmol) in 70% yield that was used in subsequent Suzuki 
cross couplings without further purification. Spectra of 3-30 was consistent with that previously 
report.
31
 
 
General protocol for Amidation of ester: 
 
To a solution of chilled ethyl 2-butynoate, 3-31, (1 equiv.) in methanol in an ice-water bath, alkyl 
amine (1.2 equiv.) was added. The reaction was stirred at 0°C overnight. Solvent was evaporated 
from the flask and residue was purified by silica gel chromatography (9:1 hexanes:ethyl acetate 
to 1:1 hexanes:ethyl acetate) to yield the desired alkynyl amide as a mixture of rotamers. Spectra 
of 3-32, 3-33, 3-34, 3-35, and 3-36 were consistent with that previously report.
REF
 
 
General protocol for hydroiodination of alkynes: 
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Alkynyl amide (1 equiv), sodium iodide (2 equiv.) and acetic acid (10 equiv.) were combined 
and heated to 110°C for 8h. In the case of the alkynyl acid, 2-butynoic acid, 3-42, (1 equiv.), 
sodium iodide (1.6 equiv.) and acetic acid (6.4 equiv.) were combined and heated to 110°C for 
3h. After cooling to room temperature, the deep red reaction mixture was diluted with water (1-2 
mL/mmol alkyne) and CH2Cl2. The mixture was treated with sodium sulfite until colorless and 
then carefully neutralized with a saturated aqueous solution of sodium bicarbonate. Organic 
fraction was separated and aqueous fraction was extracted twice with CH2Cl2. The combined 
organic fractions were washed with brine, dried over MgSO4 and evaporated to yield the desired 
iodoamide. Spectra of 3-37, 3-38, 3-39, 3-40, 3-41 and 3-43 were consistent with that previously 
report.
8,31
 
 
General protocol for amidation of acid chloride 
 
To an oven-dried Schlenk flask with a stirbar was added the iodoacid, 3-43, after which the flask 
was evacuated and backfilled with nitrogen. Dry CH2Cl2 (0.4 M 3-43) was added and the 
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solution was chilled on an ice-water bath. Oxalyl chloride (3 equiv.) was added via syringe and 
cold bath was removed following addition. After 5h at room temperature the volatile components 
were evaporated and dry CH2Cl2 (0.5 M) was added to the residual yellow oil. Flask was chilled 
in a dry ice/isopropanol bath. 4-methoxybenzylamine or alkyl amines (1.1 equiv.) were added 
dropwise by syringe followed by dropwise addition of NEt3 (1 equiv.) The mixture was allowed 
to stir overnight, warming to RT. 1 M HCl (1.5 mL per mmol) was added and the solution was 
separated with help of CH2Cl2. The aqueous fraction was extracted three times with CH2Cl2 and 
then dried over MgSO4 and evaporated. Spectra of 3-37, 3-38, 3-39, 3-40, 3-41 and 3-44 were 
consistent with that previously report.
8,31
 
 
General protocol for Suzuki cross-coupling 
 
To a flask with a stir bar was added 3-30 (1 equiv.), PdCl2(dppf), K2CO3 (6 equiv.), 3-44 (1.3 
equiv.) and alkyl iodoamide (1.5 equiv.). Flask was evacuated and backfilled with nitrogen three 
times. (Water 1 mL per mmol of 3-30) and 1,2-dimethoxyethane (9 mL per mmol of 3-30) were 
added via syringe after degassing the solvents by bubbling with nitrogen for 45 min. The flask 
was placed into an oil bath at 85°C for 3h. Once cool the mixture was poured into a separatory 
funnel, diluted with water and rinsed with EtOAc. The mixture was extracted with EtOAc three 
times and the combined organic extracts were dried over MgSO4 and evaporated to a deep red 
oil. The crude product was dissolved in CH2Cl2 and separated by silica gel chromatography (1:1 
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CH2Cl2:ethyl acetate). The cross coupled product could be found at rf ~0.4 depending on 
derivative and was rotovapped to a brown foam. 
 
General protocol for Buchwald-Hartwig amidation 
 
In a flask containing the cross-coupled product (1 equiv.), K2CO3 (6 equiv.) and Pd/X-Phos, X-
Phos (1:1 admixture, 10 mol%) were added. The flask was evacuated and backfilled with 
nitrogen three times. i-PrOH ( mL per mmol cross-coupled product) was added via syringe after 
degassing of the solvent by bubbling with nitrogen for 45 min. The mixture was heated to 85°C 
with stirring for 24h. Insoluble materials were removed by filtration through Celite and rinsed 
with CH2Cl2. The filtrate was evaporated to a brown oil that was purified by silica gel 
chromatography (1:1 CH2Cl2:ethyl acetate, rf ~0.5). 
 
General protocol for HBr deprotection 
 
The ring-closed diazanthracene product was dissolved in 48% HBr and heated to 110°C. After 
19 hours the reaction was removed from heat and allowed to cool to room temperature. The flask 
was cooled on an ice bath and rendered basic through addition of 10 M NaOH. Residual 
insoluble material was removed by filtration through hardened filter paper. The filtrate was 
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rendered acidic with 1 M HCl to form a colloidal precipitate. Mixture was filtered through 
hardened filter paper and dried under vacuum to yield the desired product. 
 
General protocol for salcomine oxidation 
 
Salcomine (6 mol%) was added to a flask containing the deprotected monophenol starting 
material (1 equiv.) and DMF (1 mL per 12 g monophenol). Flask was capped with septum and a 
syringe needle was placed into the solution. The needle was attached to a short piece of tubing 
and connected to a terminal 90 degree gas inlet adapter to which a balloon containing O2 was 
fitted. An outlet needle was allowed to puncture the septum for 1-2 min to purge atmosphere and 
was continued stirring for 3h. At three hours another portion of salcomine (6 mol%) was added 
to the flask. A third addition of salcomine (6 mol%) was added three hours later and reaction was 
left to run for 12h. Balloon was removed and DMF was blown off to produce dark red-brown 
residue. Residue was dissolved in CH2Cl2, filtered and rotovapped to dark red oil. Oil was 
dissolved in CH2Cl2 and loaded onto a chromatography column consisting of a layer of basic 
alumina under a layer of silica gel. The column was run with increasing amounts of methanol (2-
5%) in CH2Cl2 until the red product band entered the alumina layer which retained the product 
and allowed coeluting impurities to be removed. The product was released upon the addition of 
1% HOAc to the mobile phases. Fractions that were visibly red in color were evaporated and 
further purified through silica gel chromatography (5% MeOH in CH2Cl2) to yield the desired 
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DNQ derivative as a reddish solid. Spectra of IB-DNQ, P-DNQ, IP-DNQ, NP-DNQ and 3,3-
DMB-DNQ were consistent with that previously report.
8 
 
Halogenation reactions 
 
N-bromosuccinimide (9.8 mg, 0.06 mmol.) was added to a solution of IB-DNQ (16.3 mg, 0.05 
mmol) in DMF (1 mL, 0.05 M). Within 15 minutes the reaction mixture had turned dark red. 
Reaction was allowed to proceed overnight. Mixture was diluted with distilled water and 
aqueous fraction was extracted three times with ethyl acetate. Organic fraction was washed with 
brine solution, dried over MgSO4 and evaporated to a red solid. Purification through silica gel 
chromatography (1:1 CH2Cl2:ethyl acetate)lead to isolation of a red solid with a metallic like 
sheen in 95% yield. 
1
H-NMR (CDCl3, 400 MHz): δ 9.69 (bs, 1H), 6.80 (s, 1H), 4.61 (d, 2H), 2.82 (s, 3H), 2.59 (s, 
3H), 1.89 (sept, 1H), 0.92 (d, 6H). 
HRMS (ESI-TOF) calcd for C18H18N2O4Br (M+H)
+
: 405.0450, found 405.0440. 
N-chlorosuccinimide (3.6 mg, 0.03 mmol.) was added to a solution of IB-DNQ (8.0 mg, 0.025 
mmol) in DMF (1 mL, 0.025 M). Flask was placed in an oil bath at 70°C and allowed to proceed 
overnight. Flask was cooled to room temperature before diluted with distilled water and aqueous 
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fraction was extracted three times with CH2Cl2.. Organic fraction was dried over MgSO4 and 
evaporated to a orange-red oil. Purification through silica gel chromatography (1:1 CH2Cl2:ethyl 
acetate) led to isolation of four red solid products: di-chlorinated compound (rf=0.61, 41% 
yield), two monochlorinated compounds (rf = 0.52, 14% yield; rf = 0.44, 24% yield) and starting 
material (21% yield). 
Monochlorinated 
1
H-NMR (CDCl3, 400 MHz): δ 9.69 (bs, 1H), 6.79 (s, 1H), 4.62 (d, 2H), 2.78 (s, 3H), 2.60 (s, 
3H), 1.89 (sept, 1H), 0.92 (d, 6H). 
HRMS (ESI-TOF) calcd for C18H18N2O4Cl (M+H)
+
:361.0955, found 361.0955. 
1
H-NMR (CDCl3, 400 MHz): δ 6.80 (s, 1H), 4.63 (d, 2H), 2.78 (s, 3H), 2.60 (s, 3H), 1.88 (sept, 
1H), 0.93 (d, 6H). 
HRMS (ESI-TOF) calcd for C18H18N2O4Cl (M+H)
+
:361.0955, found 361.0961. 
Dichlorinated 
1
H-NMR (CDCl3, 400 MHz): δ 9.46 (bs, 1H), 4.58 (d, 2H), 2.71 (s, 6H), 1.89 (sept, 1H), 0.74 (d, 
6H). 
HRMS (ESI-TOF) calcd for C18H17N2O4Cl2 (M+H)
+
:395.0955, found 395.1. 
 
N-iodosuccinimide (5.6, 0.025 mmol) was added to a solution of IB-DNQ (6.3 mg, 0.02 mmol) 
in DMF (0.02 M). Flask was placed in an oil bath at 73°C and allowed to stir for 3.5h. Distilled 
water (1.25 mL) was added to flask and stirred at room temperature for 1h during which time a 
red precipitate had formed. Solid was filtered and rinsed with hexanes followed by ether. Solid 
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was dissolved in CH2Cl2 dried with MgSO4, and concentrated to a dark red solid. Purification 
through silica gel chromatography (1:1 CH2Cl2:ethyl acetate) led to isolation of a red solid 
product in 44% yield. 
1
H-NMR (CDCl3, 400 MHz): δ 9.60 (bs, 1H), 6.80 (s, 1H), 4.63 (d, 2H), 2.88 (s, 3H), 2.59 (s, 
3H), 1.88 (sept, 1H), 0.93 (d, 6H). 
HRMS (ESI-TOF) calcd for C18H18N2O4I (M+H)
+
: 453.0311, found 453.0308. 
 
In an Erlenmeyer flask containing a stir bar, added 2,5-dimethoxyaniline, 3-3, (5.0 g, 32.4 
mmol), xylenes (20 mL, 1.5 M),and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (5.15 mL, 39.4 mmol). 
Flask was placed in an oil bath at 120°C. Mixture was stirred for 2.25h after which the flask was 
removed from heat and allowed to cool. Concentrated to half volume and loaded onto silica gel 
for chromatographic purification (1:1 hexanes:ethyl acetate). Further purified product with 
column chromatography using increasing amounts of ethyl acetate (3:1 to 2:1 to 1:1 
hexanes:ethyl aceetate to 100% ethyl acetate). Product was evaporated to a yellow solid, 3-4, 
(6.42 g, 27.1 mmol) in 84% yield. 
1
H-NMR (CDCl3, 500 MHz): δ 9.26 (bs, 1H), 8.07 (s, 1H), 6.79 (d, 2H), 6.59 (d, 2H), 3.86 (s, 
3H), 3.77 (s, 3H), 3.59 (s, 2H), 2.32 (s,3H). 
HRMS (ESI-TOF) calcd for C12H16NO4 (M+H)
+
: 238.1079, found 238.1076 
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To a flask with a stir bar containing 3-4 (5.0 g, 21.1 mmol) was added concentrated H2SO4 (24 
mL). Mixture was stirred for 1h and then poured into a flask in an ice-water bath containing 
crushed ice. Flask was washed with distilled water and added to the flask. Concentrated NH4OH 
(60 mL) was added dropwise over 20 min to neutralize solution. Over course of neutralization a 
brown precipitate formed. A brown solid was collected via vacuum filtration to produce 3-5 
(3.68g, 16.8 mmol) in 80% yield. 
1
H-NMR (CDCl3, 400 MHz): δ 9.09 (s, 1H), 6.86 (d, 1H), 6.50 (d, 1H), 6.37 (s, 1H), 3.90 (s, 
3H), 3.82 (s, 3H), 2.60 (s, 3H). 
 
In a flask with a stir bar, 3-5 (509 mg, 2.3 mmol) was dissolved in acetonitrile (60 mL). A 
solution of cerium (IV) ammonium nitrate (CAN) was prepared separately by dissolving CAN 
(2.71 g, 4.9 mmol) in distilled water (30 mL). CAN solution was added to flask via pipette. Upon 
addition of CAN, solution changed from yellow to dark red to light red after completion of the 
addition. Mixture was allowed to stir for 3h before diluting with distilled water (50 mL). Mixture 
was extracted with chloroform three times and combined organic fractions were dried over 
MgSO4 and rotovapped to an orange to orange-red solid. Hemi-DNQ (382 mg, 2.0 mmol) was 
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obtained as a crude solid in 87% yield. Further attempts to purify the compound by silica gel 
chromatography resulted in decomposition of the product. 
1
H-NMR (CD3OD, 400 MHz): δ 6.89 (d, 1H), 6.83 (d, 1H), 6.56 (s, 1H), 2.55 (s, 3H). 
 
To flask with stir bar added 2,5-dimethoxyaniline (1.5 g, 9.7 mmol), sodium iodide (2.20 g, 14.7 
mmol) and K2CO3 (2.03 g, 14.7 mmol). Added DMF (10.5 mL, 1M) to flask and then placed in 
oil bath at 70°C. Then added and 1-bromo-3-methylpropane (1.6 mL, 14.7 mmol) to flask and 
allowed to stir for 22h. Flask was cooled and diluted with distilled water (25 mL) before 
extracting with ethyl acetate three times. Organic fractions were dried over MgSO4 and 
evaporated to a clear oil. Product was purified through column chromatography (9:1 
hexanes:ethyl acetate) to produce 3-10 (1.02g, 4.9 mmol) in 50% yield.  
1
H-NMR (CDCl3, 500 MHz): δ 6.75 (d, 1H), 6.40 (d, 1H), 6.25 (s, 1H), 3.88 (s, 3H), 3.86 (s, 
3H), 3.06 (d, 2H), 2.05 (sept, 1H), 1.12 (d, 6H). 
HRMS (ESI-TOF) calcd for C12H20NO2(M)
+
: 210.1494, found 210.1496. 
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3-10 (507 mg, 2.42 mmol) and xylenes (1.5 mL) were added to a flask and placed in an oil bath 
at 120°C.  2,2,6-trimethyl-4H-1,3-dioxin-4-one (0.38 mL, 2.9 mmol) addition to the mixture, 
turned the solution color brown. After 3h of stirring flask was taken out of bath and cooled to 
room temperature. Mixture was loaded onto silica gel column and product was eluted in 3:1 
hexanes:ethyl acetate. Product 3-10 (693 mg, 2.36 mmol) was isolated as a yellow oil in 97% 
yield. 
1
H-NMR (CDCl3, 500 MHz): δ 6.80 (m, 1H), 6.62 (d, 1H), 6.60 (d, 1H), 3.65 (s, 3H), 3.60 (s, 
3H), 3.40 (ddd, 2H), 3.08 (d, 2H), 2.02 (s, 3H), 1.65 (sept, 1H), 0.81 (d, 6H). 
HRMS (ESI-TOF) calcd for C16H24NO4 (M+H)
+
: 294.1705, found 294.1710. 
 
In a small flask with a stir bar, 3-8 (133 mg, 0.45 mmol) was added with concentrated H2SO4 
(0.52 mL). After 21h solution was poured into an Erlenmeyer flask containing crushed ice in an 
ice-water bath. Concentrated NH4OH (1.28 mL) was added dropwise to ice to neutralize the acid. 
Once all ice had melted, the mixture was filtered to collect yellow precipitate. The yellow solid 
was dissolved in ethyl acetate and diluted with an equal volume of distilled water, separated, 
dried over MgSO4 and evaporated. Residue was dissolved in CH2Cl2 and purified using silica gel 
chromatography (1:1 hexanes:ethyl acetate) to obtain 3-6 (85.8 mg, ) as a yellow oil in 69% 
yield. 
1
H-NMR (CDCl3, 500 MHz): δ 7.00 (d, 1H), 6.66 (d, 1H), 6.53 (s, 1H), 4.63 (d, 2H), 3.84 (s, 
3H) 3.83 (s, 3H) 2.61 (s, 3H), 1.88 (sept, 1H), 0.77 (d, 6H). 
114 
 
HRMS (ESI-TOF) calcd for C16H22NO3 (M+H)
+
: 276.1600, found 276.1593 
 
In a flask with a stir bar, 3-6 (87 mg, 0.32 mmol) was dissolved in acetonitrile (1.7 mL). A 
solution of cerium (IV) ammonium nitrate (CAN) was prepared separately by dissolving CAN 
(348 mg, 0.63 mmol) in distilled water (0.23 mL). CAN solution was added to flask via pipette 
and immediately solution became dark red. Mixture was allowed to stir for 1.5h before diluting 
with distilled water (10 mL). Mixture was extracted with chloroform three times and combined 
organic fractions were dried over MgSO4 and rotovapped to an orange/orange-red oil. Oil was 
dissolved in CH2Cl2 and purified by silica gel chromatography (1:1 hexanes:ethyl acetate). 
Hemi-IB-DNQ (35.9 mg, 0.15 mmol) was obtained as a red solid in 47% yield. 
1
H-NMR (CDCl3, 500 MHz): δ 6.78 (d, 1H), 6.76 (d, 1H), 6.67 (s, 1H), 4.59 (d, 2H), 2.56 (s, 
3H), 1.87 (sept, 1H), 0.91 (d, 6H). 
HRMS (ESI-TOF) calcd for C14H16NO3 (M+H)
+
: 246.1130, found 246.1133. 
 
To a flask containing Hemi-IB-DNQ (30.3 mg, 0.09 mmol) and a stir bar, sodium acetate (7.3 
mg, 0.09 mmol) and zinc dust (40.8 mg, 0.62 mmol) were added. Flask was evacuated and back 
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filled with argon three times. Acetic anhydride (0.49 mL, 5.2 mmol) was added, and flask was 
placed in an oil bath at 110°C. Solution immediately turned gray. Stirring proceeded for 1.5h and 
mixture was filtered and washed with ethyl acetate. Solution was slightly yellow and was 
rotovapped to a white solid producing 3-12 (30.2 mg, 0.09 mmol) in 74% yield. 
1
H-NMR (CDCl3, 500 MHz): δ 7.15 (d, 1H), 6.89 (d, 1H), 6.50 (s, 1H), 4.35 (d, 2H), 2.49 (s, 
3H), 2.36 (s, 3H), 2.34 (s, 3H), 1.94 (sept, 1H), 0.76 (d, 6H). 
13
C-NMR (CDCl3, 125 MHz): δ 169.3, 168.9, 163.1, 146.4, 144.4, 136.1, 133.9, 125.8, 124.3, 
118.3, 117.8, 51.4, 29.9, 27.8, 24.1, 21.5, 19.9. 
HRMS (ESI-TOF) calcd for C18H22NO5 (M+H)
+
: 332.1498, found 332.1496. 
 
Zinc dust (228 mg, mmol) and sodium acetate (29.4 mg, mmol) were added to flask containing 
Hemi-DNQ (130 mg, 0.69 mmol) and stir bar. Flask was evacuated and backfilled with nitrogen 
three times and acetic anhydride (2.6 mL, 27.5 mmol) was added. The resulting orange solution 
was placed in an 110°C oil bath and stirred for 75 min. Reaction was filtered and flask was 
rinsed with ethyl acetate. Solution was filtered to a yellow oil then dissolved in CH2Cl2 and 
diluted with an equivalent volume of distilled water. Organic fraction was extracted twice with 
CH2Cl2, organic fraction was dried over MgSO4 and rotovapped to a yellow oil. Product 3-14 (10 
mg, 0.03 mmol) was isolated as a white solid following silica gel chromatography (ethyl 
acetate). 
116 
 
1
H-NMR (CDCl3, 500 MHz): δ 7.41 (d, 1H), 7.19 (d, 1H), 7.04 (s, 1H), 2.78 (s, 3H), 2.45 (s, 
3H), 2.40 (s, 3H), 2.36 (s, 3H). 
13
C-NMR (CDCl3, 125 MHz): δ 169.8, 169.6, 168.9, 156.5, 148.1, 145.3, 144.9, 141.3, 122.6, 
121.8, 120.1, 118.9, 31.2, 23.3, 21.8, 21.2. 
HRMS (ESI-TOF) calcd for C
16
H
16
NO
6
 (M+H)
+
: 318.0978, found 318.0979. 
 
To a flask containing a stir bar and 3-5 (167 mg, 0.76 mmol), concentrated HBr was added (1.8 
mL). An air condenser was fitted to the flask and the flask was placed in an oil bath at 145°C. 
The solution was heated for 24h and then poured into distilled water (20 mL) to form a 
precipitate. Precipitate was collected through vacuum filtration to produce 3-17 (115 mg, 0.60 
mmol) as a light brown solid in 79% yield. 
1
H-NMR (CDCl3, 400 MHz): δ 9.68 (s, 1H), 9.45 (s, 2H), 6.72 (d, 1H), 6.37 (d, 2H), 6.12 (s, 
1H), 3.32 (s, 3H). 
HRMS (ESI-TOF) calcd for C10H10NO3 (M+H)
+
: 192.0661, found 192.0661. 
 
Dose-dependent in vitro IB-DNQ cytotoxicity assay 
Cells were seeded at 5000 cells per well in 96 well plates and allowed to attach. Media 
containing varying concentrations (0.003-100μM) of IB-DNQ, Hemi-DNQ or Hemi-IB-DNQ 
was made and cells were exposed for 2–h. Treatment media was removed and replaced with 
drug-free media and cells were allowed to grow for 48 h. To investigate the inhibitory effects of 
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dicoumarol on NQO1 activity, cells were treated with vehicle (DMSO) or with a combination of 
25 μM dicoumarol with Hemi-DNQ, Hemi-IB-DNQ or IB-DNQ for 2-h. Viability was assessed 
using the sulforhodamine B (SRB) assay.
33
 Percent death was plotted against concentration and 
fitted to a logistic dose response curve. 
 
Animal dosing and sample collection 
Four, healthy, intact, female domestic shorthair cats weighing 4-5 kg were used for all 
pharmacokinetic and toxicologic studies. IB-DNQ, P-DNQ, NP-DNQ and IP-DNQ were 
dissolved into HPβCD and sterile water was administered intravenously (2.0 mg/kg IV). Cats 
received a minimum of three doses of each DNQ derivative with a minimum washout period of 2 
weeks between dosing. Sample collection times for all methods of administration were 0, 10, 20, 
30, 40, 60, 120, 240, 480 min and 24 h post administration. Cats were monitored peri- and post-
derivative administration to document clinical symptoms. Upon completion of DNQ derivative 
administrations, the cats were monitored for an additional 9 months for assessment of delayed 
toxicity. All experiments with healthy research cats were approved by the University of Illinois 
Animal Care and Use Committee. 
 
Plasma IB-DNQ quantification method 
Plasma samples were analyzed with the 5500 QTRAP LC/MS/MS system (Sciex, 
Framingham, MA) in Metabolomics Lab of Roy J. Carver Biotechnology Center, University of 
Illinois at Urbana-Champaign. Software Analyst 1.6.2 was used for data acquisition and analysis. 
The 1200 series HPLC system (Agilent Technologies, Santa Clara, CA) includes a degasser, an 
autosampler, and a binary pump. Multiple reaction monitoring (MRM) was used for 
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quantification of IB-DNQ, P-DNQ, IP-DNQ and NP-DNQ with DNQ as the internal standard. 
The detection limit was 1.0 ng/mL. 
 
Pharmacokinetic profile of IB-DNQ 
Pharmacokinetic analyses were performed using a non-linear regression program 
(Winnonlin, version 5.1) (Pharsight Corporation, Cary, NC). The area under the curve (AUC), 
terminal half-life (t1/2 β), volume of distribution at steady state (Vdss), total clearance (Cl), 
maximum drug concentration (Cmax) and time at which Cmax was achieved (Tmax) were 
determined. 
 
Computational Modeling 
 DNQ and derivatives were built and a 10Å water layer was built around the molecule. 
The derivative structure was energy minimized using MOE with a MMFF94x forcefield using 
gas phase calculations and a cutoff of 0.01. Charges were fixed using an MMFF94 forcefield. 
The NQO1 structure was downloaded from the PDB (1DXO). One of the homodimers was 
extracted and protonated. Derivatives were then modeled into the protein active site, using the 
site of duroquinone to identify the active site. Derivatives were docked using the Dock program 
in MOE, using Triangle Matching for placement of the molecules and London dG for rescoring 
of the placement. Using Lig X, the top configuration was protonated and energy was minimized. 
Images of this minimized conformation were taken for comparison between derivatives. 
Similarly the NADPH cytochrome P450 reductase structure was downloaded from the PDB 
(3QFR), a single homodimer was extracted and protonated, and derivatives were modeled into 
the presumed protein active site, using the placement of the cofactors to identify the active site. 
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Derivatives were docked and the top configuration was taken for analysis between derivatives as 
described for NQO1. 
 
ROS Generation Assays 
Cells (JHU029, MDA-MB-231 NQO1±) were treated with DNQ derivatives (1, 5, 10, 25 
μM) for 3h. After 3h compound was washed out and replaced with media containing 5 μM 
MitoSOX red (ThermoFisher, Waltham, MA). After 10 min cells were washed and trypsinized. 
Cell suspensions were then analyzed via flow cytometry using the appropriate wavelengths for 
MitoSOX red. Samples were compared to the DMSO treated control sample and reported as 
fold-change compared to DMSO control. 
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